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ABSTRACT
Animal studies have demonstrated a lower myocardial extraction fraction and earlier 
“roll-off’ in the myocardial uptake o f Tc-99m tetrofosmin compared to Tc-99m 
sestamibi, giving rise to concerns that the consequent reduction in defect contrast 
could result in underestimation o f perfusion defects by Tc-99m tetrofosmin. There are 
no large studies comparing the two agents in the same group o f patients. It has been 
suggested that differences between these two agents are most likely to manifest in the 
setting o f mild to moderate coronary disease, where defect contrast is already 
relatively low, and during the use o f vasodilator stress where the higher rates of 
myocardial blood flow induced make tracer roll o ff more likely. Accordingly, in this 
prospective, two-centre (UK and Canada) study, 81 carefully chosen patients with 
mild to moderate coronary stenosis (50-90% stenosis in up to 2 major epicardial 
vessels, no previous myocardial infarction) and 7 patients with less than 5% 
probability o f coronary disease underwent dipyridamole SPECT imaging with Tc- 
99m sestamibi and Tc-99m tetrofosmin in random order. Images were interpreted 
blindly by a panel o f independent, experienced readers, and were analysed visually to 
determine the presence o f perfusion defects and reversibility, and quantitatively using 
the CEqual programme to determine defect extent and severity.
Two additional readers undertook a second blinded reading o f the scans o f patients 
recruited by the UK centre. These were also analysed using the Liege quantitative 
programme. This subgroup analysis was intended to serve as a control to corroborate 
the results o f the larger study.
Tc-99m sestamibi detected reversible perfusion defects in 365 segments compared 
with 285 by Tc-99m tetrofosmin (p<0.0001), and demonstrated a larger extent of
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perfusion defect as determined by the percentage o f left ventricular myocardium 
involved (mean ± SD, 15.8%± 12.3 and 12% ±11.9 for Tc-99m sestamibi and Tc- 
99m tetrofosmin, respectively, p<0.03). The defect /normal wall ratio was 
significantly lower with Tc-99m sestamibi (0.60 ± 0.15) compared to Tc-99m 
tetrofosmin (0.73 ± 0.14, p = 0.01) indicating better defect contrast with Tc-99m 
sestamibi. In addition, Tc-99m sestamibi more often correctly predicted the presence 
o f disease in more than one coronary artery. Diagnostic sensitivity was 63% and 58% 
for Tc-99m sestamibi and Tc-99m tetrofosmin, respectively (p=0.09), and the 
accuracy for detection o f disease in individual coronary territories was similar. There 
was overall concordance o f 78% (Kappa =0.67) and 86% (kappa = 0.67) for 
categorisation o f scans and individual segments, respectively, as normal, reversible 
and fixed. The quality o f images produced by the two agents was comparable.
Such differences in ability o f two commonly used perfusion tracers to determine the 
presence, extent and severity o f reversible perfusion defects could have significant 
diagnostic and prognostic implications.
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CHAPTER 1 
HISTORICAL REVIEW
1.1 THE DEVELOPMENT OF RADIONUCLIDE AGENTS FOR CARDIAC 
IMAGING
The initial use o f radioactive materials for evaluating the cardiovascular system dates 
to the pioneering and extensive measurements into the velocity o f blood flow in man 
performed by Blumgart and Wiess in 1927. Their investigations sought, among other 
things, to employ the transpulmonary transit time as a measure o f pulmonary vascular 
volume. Historically, Blumgart and Weiss were restricted in their investigations to the 
use o f radium products, as these were the only radioactive substances then available. 
It was thought by them that their tracer substance was the ionic form of Radium C 
(Brucer 1969). This alpha, beta and gamma emitter with a half-life o f 19.7 min is 
derived from 3.8 day gaseous radon, in turn a daughter product o f 1602 -yr. radium- 
226. Thus radium kept for treatment o f cervical and other cancers was utilised as a 
generator for the provision o f a short-lived radionuclide, anticipating current practice 
by nearly half a century.
In 1948 Prinzmetal recorded the passage of radiosodium (Na-24) through the cardiac 
chambers by a direct-writing Geiger-Mueller counter and chart recorder, and called 
the procedure radiocardiography. He also termed the waves corresponding to the 
passage o f blood through the right and left sides o f the heart the R-wave and L-wave 
respectively. In 1962 phasic count changes during a cardiac cycle were first identified 
using single probe studies (Folse et.al 1962). The principles o f the gamma camera 
were first put forward by Anger in 1957, and in 1963 (Blender et.al 1963), gamma 
cameras were first used to image individual chambers of the heart.
In 1952, Yates suggested that P-32 may be used to detect regions of reduced 
myocardial blood flow. The myocardial accumulation o f radioactive potassium and 
rubidium was first demonstrated by Love in 1954 and, in 1956, Sapirstein suggested 
a relationship between tracer extraction and myocardial blood flow. Eight to ten years 
then elapsed before Carr and co-workers suggested the application o f these 
observations to imaging of the myocardium. In two prototype animal studies (Carr, Jr. 
et.al 1964), (Carr et.al 1962), these authors demonstrated that, in the case o f both 
rubidium-86 and caesium-131, significant amounts o f radioactivity could be detected 
within the normal myocardium, and that following experimental coronary ligation, 
zones o f decreased radioactivity could be visualised. However, potassium-42 and 
rubidium-86 were not ideal for imaging with gamma scintillation detectors because 
the excessively high energy gamma radiation was difficult to detect and the presence 
o f beta radiation resulted in an excessive radiation dose to the patients.
The first clinical use o f myocardial perfusion imaging was the demonstration of 
transiently ischaemic myocardium by exercise testing in patients using potassium- 43 
by Zaret in 1973. This was followed by the use o f rubidium-81 by Berman in 1975. 
However, imaging with potassium-43 was subject to the same disadvantages as 
potassium-42. Myocardial perfusion imaging with rubidium-81 was accomplished 
with a special collimator that prevented penetration o f the high-energy emission of 
both rubidium-81 and rubidium-82, the latter being a contaminant in commercially 
available rubidium-81. Although high sensitivity and specificity values were reported 
for the detection o f coronary artery disease, image interpretation using a pin hole 
collimator is difficult if the heart is not well centred within the camera’s field o f view. 
Also, camera sensitivity is not uniform across a flood field; peak activity occurs in the
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centre. Thus, patient positioning becomes critical, since small shifts within the field 
have the potential to create differences in image intensity, making analysis o f regional 
tracer uptake pattern very difficult.
It was the introduction o f Thallium-201 as a tracer for myocardial perfusion imaging 
that firmly established nuclear cardiology as a major diagnostic modality as we know 
it today. The use o f thallium-201 as a perfusion tracer was first suggested because of 
its similarity to potassium-43. Lebowitz (1975) and Strauss (1975) demonstrated its 
superior physical properties for imaging with a scintillation camera in the form of 
lower photon energy (60 to 80 keV) and efficient myocardial extraction. Tl-201 
scintigraphy was performed in goats in 1975 by Bradley-More et al. In 1975 
Wackers et al described the non-invasive visualisation of acute myocardial infarction 
in man with thallium-201. In 1976, Ritchie et al and Shames et al first described 
thallium-201 myocardial perfusion imaging for the detection o f coronary artery 
disease in man. Initial studies of thallium-201 myocardial perfusion imaging utilised 
two separate injections for the rest and stress studies, but this changed with the 
description of redistribution by Pohost in 1977 and, thallium-201 became widely 
accepted as a tracer for myocardial perfusion imaging. Its utility for the diagnosis and 
risk stratification in patients with known or suspected coronary artery disease is now 
firmly established.
Among all the potassium analogues, thallium-201 has the most favourable 
characteristics for gamma camera imaging. However, it too has physical properties 
that are not ideal (Beller G 1995a). To be used optimally with conventional 
scintillation cameras, a radionuclide should have its major photopeak in the range of
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100 to 200 keV. Although the long half-life o f thallium-201 (74 hours) provides a 
reasonable shelf life and obviates the need for daily delivery from the site of 
production, it necessitates a longer time interval between sequential studies in the 
same patient, and results in a high radiation burden to the patient. Cyclotron 
production results in a relatively high cost. To circumvent these limitations, 
investigators attempted for over a decade to develop a myocardial perfusion agent 
labelled with technetium-99m, a tracer with ideal physical properties for scintillation 
camera imaging. In 1982, investigators at the Peter Bent Brigham hospital, USA 
announced the development o f Tc-99m ligands (Jones et.al 1984). Technetium-99m 
has many advantages over thallium-201 for gamma camera imaging including its 
monoenergetic gamma of 140keV, half-life o f 6 hours, on-site preparation ensuring 
easy availability and low cost (Beller 1995a). The classes of Tc- labelled radiotracers 
include the isonitriles (Tc-9^m -t-butyl isonitrile or TBI, Tc~99m carboxyisopropyl 
isonitrile or CPI, and Tc-99m sestamibi or MIBI), Boronic Acid Adducts o f 
Technetium Dioxime (BATO) compounds including Tc-99m teboroxime, 
Diphosphene agents including Tc-99m tetrofosmin, Q-compounds (Tc-99m 
furifosmin) and Tc-99m NOET. Although all these agents have been subjected to 
clinical trials, only Tc-99m sestamibi and Tc-99m tetrofosmin have gained 
widespread clinical utility. Clinical use o f other compounds have been hindered by 
high hepatic and pulmonary uptake (TBI, CPI) (Holman et.al 1984); (Sia et.al 1986); 
(Holman et.al 1987) or rapid washout from the myocardium (Tc-99m teboroxime) 
(Stewart et.al 1990); (Leppo et.al 1990; Seldin et.al 1989).
The introduction o f Tc-ligands into nuclear cardiology has resulted in perfusion 
scintigrams of superior quality, with excellent diagnostic accuracy and prognostic
15
value in patients with known or suspected coronary artery disease. Simultaneous 
advances in computer technology have enabled ECG-gating o f Tc-99m scans that can 
also provide data on regional and global left ventricular function.
The quest for the ideal myocardial perfusion agent continues and further efforts are 
being directed towards the development of agents that combine the favourable 
properties of thallium-201 and Tc-99m. Meanwhile, myocardial perfusion imaging 
continues to be a cornerstone in the non-invasive assessment o f patients with coronary 
artery disease.
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CHAPTER 2 
NUCLEAR PHYSICS
2.1 BASIC ATOMIC STRUCTURE
The atom is composed o f positively charged particles called protons, negatively 
charged particles called electrons and neutral particles called neutrons.
The protons and neutrons (collectively called the nucleons) are located in the nucleus, 
which is relatively small compared to the size of the atom (Parker et.al, 1984). The 
nucleus therefore, has a net positive charge. The atomic number (Z) denotes the 
number o f protons in the atom. The total number o f nucleons is the atomic mass (A). 
For example, 13 *1 denotes an atom of Iodine with atomic mass 131.
Electrons orbit in shells around the nucleus. These shells are conventionally labelled 
K, L, M... etc. The maximum number o f electrons in each shell is 2n2 where n is the 
number o f the shell from the nucleus (IO l, L=2, etc). Atoms with filled shells are 
chemically inert. Electrons possess kinetic and potential energy, with energy 
decreasing progressively away from the nucleus. The attractive electrostatic force 
between the positively charged nucleus and negatively charged electrons binds the 
atom together (Fig.2.1).
Normally, nuclei are in the ground state. Excited nuclei transform to the ground state 
by emission o f electromagnetic radiation in the form of gamma rays. Similarly, when 
electrons move from an inner to an outer orbit, electromagnetic energy is given off in 
the form of X-rays. Electromagnetic radiation is emitted in “packets” o f energy called 
photons.
A nuclide is a species o f an atom with a specific atomic number, neutron number and 
in a defined nuclear state. Normally, nuclei in an excited state decay immediately to
18
Fig 2.1 Atomic structure: central nucleus 
surrounded by electrons in orbits.
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the ground state. When the nucleus o f a nuclide remains in an excited state for 
minutes to hours, it is said to be in a metastable state (represented by m). When two 
or more nuclides have the same atomic number, they are called isotopes. Hence 
isotopes are different nuclides o f the same element differing in neutron number. For 
e.g. there are 23 isotopes o f iodine, 117I to 1311.
2.2 RADIOACTIVE DECAY
Nuclides that do not have a stable combination o f neutrons and protons spontaneously 
decay into a more stable “daughter nuclide” (Parker et.al 1984). One or more such 
decay reactions will result in the formation o f a stable nuclide. The nucleus o f the 
daughter nuclide is usually in an excited state after the decay reaction and will 
transform to the ground state by emission o f gamma rays (Fig.2.2). Such unstable 
nuclides are said to be radioactive (hence the terms radionuclide and radioisotope) and 
are used for imaging in nuclear medicine.
Radioactive decay may occur by the following mechanisms, depending on the relative 
number o f neutrons and protons on the atom (Parker et.al 1984).
2.2a P-Emission
Nuclides with an excess of neutrons decay by emitting a negatively charged particle 
(p- particle) from a neutron resulting in the formation of a proton, which stays in the 
nucleus. Nuclides produced in reactors generally decay in this manner.
E.g. P32 to S32
20
particle Gamma ray
parent daughter in daughter in
excited state ground state
Fig 2.2 Radioactive decay
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Decay by this mechanism occurs when the nucleus has a deficiency o f neutrons. Here, 
a proton emits a positron (positively charged particle) and the resulting neutron 
remains in the nucleus.
The positron is usually annihilated by combining with an electron from the 
surrounding atom (annihilation reaction) resulting in the emission o f 2 photons 
(gamma rays o f 511 keV) at 180° to each other. The sensitivity o f detection of gamma 
rays o f this energy by a standard gamma camera would be low, but this phenomenon 
is used for coincidence detection in Positron Emission Tomography (PET). Standard 
gamma cameras may be adapted for this technique by using high-energy collimators.
2.2c Electron Capture
In this form o f radioactive decay, an electron is captured from one o f the orbits, 
usually the K-shell, and combines with a proton to form a neutron, 
e.g. Chromium-51 to Vanadium-51.
Agents that are cyclotron produced usually have an excess o f charged particles and 
usually decay by positron emission or electron capture (or both).
2.2d Isomeric transition
When a metastable nuclide decays, it emits only gamma rays and no particulate 
radiation, since it is just an excited state of the decay product. Sometimes however, 
the energy, instead of being emitted as photons, may be used to eject an electron (a 
process called internal conversion) which is then emitted as particulate radiation.
2.2b Positron emission
E.g. Tc-99m
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Here, 2 neutrons and 2 protons are emitted . The resulting radiation has a very short 
range and high toxicity and therefore, is not used in nuclear medicine.
The energy o f electromagnetic radiation emitted by the radionuclide is all-important 
in nuclear medicine. The ideal energy is a compromise between the ability o f the 
radiation to penetrate tissue (higher the better) and the ability of the detector crystal to 
stop the gamma ray. Energies around 150 keV are ideal and those between 100 to 200 
keV are preferred. Hence Tc-99m which emits gamma rays o f 140 lceV is widely used 
in nuclear medicine. Radionuclides which have significant particulate emissions (a or 
(3 emissions) are suboptimal for use clinically since these short range emissions 
increase the radiation burden without significantly contributing to image quality. 
Decay by isomeric transition and electron capture result in significantly less 
particulate emissions.
2.2e a - decay
2 3
The method o f production o f radioactive nuclides determines several important 
properties including (Parker et al, 1984):
1. Cost
2. Ease o f availability
3. High or low specific activity
4. Amount o f radionuclide impurity
5. Other specific properties, for e.g., nuclides produced in a reactor are normally beta 
emitters.
The principle sources o f radionuclides are the following (Parker et.al 1984)
1. Naturally occurring radionuclides e.g. Radium-226, Potassium-40, Carbon-14
2. The nuclear reactor
• Neutron Bombardment e.g., phosphorous-32
• Fission products
3. The cyclotron e.g. thallium-201
4. Radionuclide generators e.g. Technetium-99m
2.3a Preparation of Technetium-99m
Since its introduction in the 1970s Tc-99m has become the most widely utilised 
radionuclide for organ visualisation. Apart from its favourable physical characteristics 
for gamma camera imaging, one o f the important reasons for its widespread 
popularity is its ready availability in hospital through production by a generator.
The requirement o f generator systems is that the radionuclide o f interest should be a 
short-lived daughter o f a relatively longer-lived radionuclide from which it can be 
separated. Either physical or chemical methods can be used to separate the two
2.3 PRODUCTION OF RADIOACTIVE NUCLIDES
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radionuclides and this can be done either continuously or, more usually, when 
required.
For the Molybdenum-99- technetium-99m generator (Fig 2.3), the parent 
molybdenum is obtained from a nuclear reactor. The most common method employed 
to separate the daughter technetium is ion exchange. The molybdenum is prepared as 
ammonium molybdate (NH4)+(Mo04)’ and adsorbed on alumina contained in a glass 
or plastic column. The Mo-99 decays and the Tc-99m is formed as the pertechnetate 
ion TCO4". When a saline solution is passed through the column the chloride ions 
exchange with the (Tc04)'but not the (M0O4)" ion. After passing through the column 
the saline solution contains sodium pertechnetate Na+(99Tcni04)'. The column is said 
to be eluted by the eluent (saline) to give the eluate (sodium pertechnetate in saline). 
After elution the Tc-99m activity on the column builds up and the column can be re­
eluted. Saline can be passed over the alumina by either o f two systems. Positive 
pressure systems operate either by using pressure to pass the saline through the 
column or by allowing the saline to flow through by gravity. Negative pressure 
systems use vacuum vials to suck the saline through from a reservoir. The columns 
are enclosed in lead for radiation protection. They are sterilised by autoclaving and 
will produce a sterile eluate. The Tc-99m in the eluate is essentially carrier free and 
has low concentrations o f the radioactive element. The decay product Tc-99 is also 
radioactive, but as its half life is 2.1 x 105 years, about 10 becquerels o f Tc-99 are 
produced from decay o f 3 gigabecquerels o f Tc-99m.
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Eluting solvent
Glass column
Adsorbed parent 
activity + 
daughter activity 
(grown)
Evacuated collecting vial 
Eluted daughter activity
Lead shield
Adsorbent material
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CHAPTER 3 
INSTRUM ENTATION
3.1 DETECTION OF RADIATION
Certain materials have the property o f absorbing gamma rays or X- ray photons and 
converting them to flashes o f light called scintillations. The sodium iodide (Nal) 
crystal is the most commonly used detector in clinical practice (Beller 1995b). It is 
usually doped with small amounts o f thallium (29.5% Tl203 and 70.5% Tl205) which 
greatly increases the production o f light. When the gamma ray enters the crystal the 
photons interact with the electrons in the crystal. The energy thus produced is 
absorbed in the crystal resulting in the production of light, the intensity o f which is 
proportional to the amount of absorbed energy. The crystal is usually 0.25 to 0.5 
inches thick. The ability o f the crystal to stop gamma rays (sensitivity) depends on its 
density and thickness. However, intrinsic resolution varies inversely with thickness. 
The higher the energy o f the gamma radiation, the greater the thickness required to 
maintain sensitivity.
The detector contains light - sensitive devices called photo-multiplier tubes which 
detects these scintillations. Photomultiplier tubes are composed o f a photocathode 
facing the window through which light enters, a series of metallic electrodes called 
dynodes arranged in a geometric pattern and connected to increasingly higher 
voltages, and an anode (Fig.3.1). The photomultiplier tube, which is optically linked 
with the scintillation crystal, converts the light from the crystal to electrical energy by 
the emission o f electrons from the photocathode in proportion to the amount of light 
received. The original number o f electrons released is amplified by a factor of 
approximately 1 million by the dynodes and collected by the anode. This bunch of 
electrons are finally shaped by a pre-amplifier to generate an electrical pulse. The
28
Preamplifier 
and Amplifier
Anode
Dynode Dynode
Nal(Tl) Crystal Photo Cathode
vy\y\y
y-rays
Fig 3.1 Photomultiplier tube
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height o f this pulse or voltage created by a single scintillation is directly proportional 
to the amount of light released within the crystal, which in turn, is proportional to the 
energy o f the gamma ray absorbed by the crystal. The output o f the preamplifier is 
directed to a linear amplifier for amplification to several volts.
A pulse height analyser or selector is an electronic device used to select pulses from a 
range o f available energies to be counted. An energy window is created in this 
manner, and pulses corresponding to gamma rays o f energies outside this window are 
rejected and not recorded. This ensures that energies below a certain threshold are 
rejected thus eliminating gamma rays that have lost their original energy and direction 
during a Compton scatter event. The window for the energy range is usually set with 
an upper level discriminator and a lower-level discriminator. With respect to Tc-99m, 
a 20% window for 140keV would range from 126 keV to 154 keV.
3.2 MEASUREMENT OF RADIOACTIVITY
Intrinsic efficiency is a measure o f the capability of the detector to detect radiation and 
is defined as the ratio o f the number o f alpha, beta or gamma rays detected to the 
number o f rays of a given radiation incident on the sensitive volume of the detector.
Sensitivity is the counting rate obtained from unit activity o f sample. It is usually 
measured by calibration against a standard source.
Dead time or resolving time is a measure o f the capability o f a radiation detector to 
detect rays at high count rates or radiation flux. With high count rates or high 
radiation flux (intensity) the second ray arrives and interacts with the detector while it
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is still processing the first ray. Ideally the detector should have as short a dead time as 
possible.
Energy resolution is the ability o f a detector to distinguish two radiations of different 
energies. Full Width at Half Maximum (FWHM), is approximately the minimum 
difference necessary between the energies o f two gamma rays if they are to be 
identified as possessing different energies (Fig. 3.2).
3.3 GAMMA CAMERAS
The basic types o f Nal(Tl) detectors to localise scintillation events are the single­
crystal (Anger) camera and the multi-crystal camera. There are also nonimaging 
probes, which can monitor radioactive counts, but do not produce an image of the 
organ.
3.3a Single-crystal camera
A diagrammatic representation o f the basic single -  crystal camera, first developed by 
Anger in 1956 is shown in Fig 3.3.
The single -  crystal camera uses a large Nal (Tl) crystal with a set o f photomultiplier 
tubes arranged in a hexagonal array. The crystal is usually 0.25 to 0.5 inches thick, 
with dimensions up to 500 mm. The thinner the crystal, the better the resolution. The 
trade-off for better resolution is a reduction in sensitivity. The gamma rays emanating 
from the source are initially “ collimated” to allow only gamma rays o f a desired 
direction to strike the crystal. This is required so that an accurate image o f the
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Fig 3.2 Diagrammatic representation of Full Width 
at Half Maximum (FWHM). Typical values for 
detection of Tc-99m gamma rays by Nal detectors 
approximate 15% (Parker et. al. 1984).
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distribution o f radioactivity in a patient can be produced. The location o f absorption 
o f gamma rays in the scintillation camera should be related to the origin o f these rays 
within the patient. The gamma rays pass through the holes o f the collimator and are 
absorbed by the crystal and give rise to scintillation. The photomultiplier tubes detect 
the light given off by the scintillation and feed the output into a computer-directed 
analyser. The circuitry o f this analyser permits the determination o f the point at which 
each scintillation occurs and x- and y co-ordinates are assigned to the event. A pulse 
is also generated, which represents the summed output o f all photomultiplier tubes. 
This pulse is analysed by the pulse height analyser that has been programmed to 
accept only a certain range o f energies. The output o f the pulse height analyser is 
called the z pulse.
The x, y and z signals can be recorded using a cathode ray tube in analogue format. 
When the z pulse is accepted and enters the cathode ray tube, there is an emission of 
electrons from the electron gun. These electrons then strike the phosphor screen o f the 
cathode ray tube, producing light recorded as a dot on the photographic film. The 
position o f the dot corresponds directly to the localisation o f radioactivity in the 
patient. Thus an image is obtained by a collection o f such dots.
Collimators are lead disks containing multiple holes that block gamma rays that are 
not travelling in a desired pathway. The parallel hole collimator is the one most 
commonly used for cardiac imaging and has a large number o f parallel holes aligned 
perpendicular to the face o f the crystal. The larger the diameter o f the holes or the 
shorter the length o f the holes, the greater the sensitivity of the detector but lower the 
spatial resolution o f the detector system. A compromise between the two is termed a
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general purpose collimator which is intermediate with respect to sensitivity and 
resolution. For imaging with Thallium-201 a general purpose collimator is preferred 
to ensure collection o f adequate counts in a shorter time since perfusion defects may 
fill in rapidly by redistribution. General purpose collimators have nearly the same 
resolution as high resolution collimators, but loose resolution more rapidly with 
increasing distance from the collimator face. With technetium-99m agents, the count 
rate is sufficiently high to allow the use o f a high resolution parallel-hole collimator 
(Beller 1995b; Gemmell et.al 1998). In addition, collimators are also specific to 
different spectrums of energy: low (<140 keV), medium (<260 keV) and high (<400 
keV) energy collimators.
3.3b Multicrystal cameras
A multicrystal gamma camera consists o f a detector comprising 294 Nal (Tl) crystals 
arranged in 14 rows and 21 columns. Each row and column has a photomultiplier 
tube. The multicrystal camera has a high count rate capability and is able to more 
accurately record the count rate from an intense radioactive source. Elowever the 
detection o f an interaction does not include collection o f position information, 
therefore higher count rates can be processed without appreciable count rate loss or 
positioning errors. The multicrystal camera is the instrument used for first-pass 
imaging of a radionuclide through the central circulation. Its high sensitivity results 
in the recording o f more than 400,000 counts per second in the image. The downside 
o f the multicrystal camera is the poor spatial and energy resolution.
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Three nonimaging devices have been developed for assessment of dynamic changes 
in radioactivity within the blood pool o f the left and right ventricles. These are the 
Nuclear stethoscope (Bacharach et.al 1977), the VEST (Wilson et.al 1983)and the 
Cardioscint (Broadhurst et.al 1991). These devices allow recording o f counts in real 
time and can be linked to an electrocardiographic signal from the patient. Beat-to beat 
left ventricular time-activity curves are recorded and the left ventricular ejection 
fraction can be calculated. The VEST and Cardioscint can be used for ambulatory 
monitoring.
3.4 SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT)
There are mainly two types o f image acquisition.
In planar imaging, two-dimensional projections of the distribution of the 
radiopharmaceutical in the patient are obtained by acquiring images in 3 or 4 standard 
views (anterior, 45° left anterior oblique and 70° left anterior oblique) for a 
predetermined time (8 to 10 min per view). This two- dimensional representation of 
three -dimensional information results in superimposition o f structures o f different 
depths and leads to tissue attenuation, segmental overlap and poor regional 
separation. For cardiac, imaging this makes detection and localisation o f small 
perfusion defects difficult.
Tomographic imaging on the other hand, collects data from multiple views and uses 
this information to reconstruct an image o f the organ. Since multiple orthogonal views 
are acquired, three-dimensional information is obtained and the above problems
3.3c Non-imaging probes
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associated with planar imaging are overcome. Emission computed tomography can be 
used to detect annihilation coincidence detection from positron emitters (positron 
emission tomography or PET) or gamma radiation from single-photon emitters 
(Single-photon emission computed tomography or SPECT).
SPECT imaging may be longitudinal in which the imaging plane through the patient 
is parallel to the long axis o f the body or rotational where it is transverse.
Rotational tomography is the preferred technique for cardiac SPECT imaging and 
images are acquired by rotating a gamma camera (mounted on a gantry) around the 
patient. A 180° orbit is preferred to 360° since imaging the myocardium from the 
posterior aspect acquires highly attenuated and scattered photons (Garcia et.al 1990). 
The 180° arc usually extends from the 45° right anterior oblique position to 45° left 
posterior oblique, and could be either circular or elliptical. Despite the camera being 
closer to the patient in elliptical tomography, circular orbits are preferred because of 
the regional non-uniformity resulting in image artefacts associated with the former 
(Beller 1995b; Garcia et.al 1990). The most commonly adopted technique o f cardiac 
SPECT acquisition is the ‘ step and shoot’ mode in which the camera makes 32 or 64 
stops and acquires gamma rays for 20 -60 seconds during each stop. Each projection 
is corrected for field non-uniformity and misalignment o f the centre o f rotation. For 
Tc-99m imaging, the high photon energy enables the use o f a high resolution 
(relatively low sensitivity) collimator. For thallium-201 imaging a general purpose 
(medium resolution, high sensitivity) collimator is preferred.
After acquisition is complete, transverse axis images are reconstructed by back- 
projecting planar profiles obtained at each angle on to a computer array. A high-pass 
Ramp filter is used to correct for the blurring effect produced by back projection ( the 
process is therefore termed filtered back-projection). To compensate for the
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enhancement o f high frequencies (noise) that occur as a result o f ramp filtering, this is 
usually combined with a low-pass (smoothing) filter such as the Butterworth or 
Hanning filter (Gemmell et.al 1998; Zubal et.al 1997). In this way, 1 pixel thick 
transverse axis tomograms of the heart are created, and then reoriented to produce 
horizontal long-axis, vertical long-axis and short axis tomograms (fig 3.4). These are 
then displayed in a conventional format in either grey scale or colour scale to enable a 
visual, semi-quantitative analysis o f regional radionuclide tracer uptake by the 
myocardium (Fig 3.5).
SPECT systems with 2 and 3 detector heads are available which reduce imaging time 
and improve resolution.
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CHAPTER 4
DIAGNOSIS OF C O R O N A R Y  
A R TE R Y DISEASE
The diagnosis o f coronary artery disease may be established by coronary 
arteriography or by non-invasive tests which include exercise electrocardiography, 
myocardial perfusion imaging, and stress echocardiography. Positron emission 
tomography (PET), magnetic resonance imaging (MRI) and electron beam CT 
(EBCT) have limited clinical application for the assessment o f patients with coronary 
artery disease, and are still largely research tools.
4.1 USE OF CORONARY ARTERIOGRAPHY AS THE GOLD STANDARD.
Coronary arteriography provides anatomical information about the patency of 
coronary arteries and is currently considered the gold standard for the diagnosis of 
coronary artery disease. A stenosis o f greater than 50% diameter severity is 
considered to be “significant” . However, there are several problems associated with 
the use of coronary arteriography as the gold standard in the assessment o f patients 
with known or suspected coronary artery disease.
The angiographic evaluation o f the epicardial segments of the three major coronary 
arteries provides purely anatomical data, and cannot provide information on the 
presence or degree of myocardial ischaemia occurring under conditions of stress. A 
significant inter-observer variability in the visual analysis of coronary arteriograms is 
well established such that the functional significance o f intermediate degrees of 
stenosis is often difficult to determine based on anatomy alone (DeRouen et.al 1977; 
Detre et.al 1975; Grondin et.al 1974; Marcus et.al 1988a; Marcus et.al 1988b; Uren 
et.al 1994; White et.al 1984; Zir et.al 1976). Even the use o f quantitative techniques 
has not obviated these limitations (Cusma et.al 1995; Keane et.al 1995; Mancini et.al 
1987; Zijlstra et.al 1987). Although coronary arteriography is a relatively safe
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technique, it is associated with a small (0.01%) but definite risk o f serious 
complications including death, myocardial infarction and stroke (Adams et.al 1973; 
Bourassa et.al 1976; Davis et.al 1979; Green et.al 1972; Judkin et.al 1974; Mortensen 
1967; Takaro et.al 1973).
Non-invasive techniques, on the other hand, assess the functional significance of 
coronary stenoses and enable an accurate estimation of the probability o f future 
adverse cardiac events, based on which therapeutic decisions may be safely made. 
Thus patients at high risk would have early coronary arteriography and intervention 
while unnecessary invasive procedures could be avoided in the low risk groups. 
Several studies have established that a functional approach to the management of 
coronary artery disease is both safe and cost effective (Marwick et.al 1999; Shaw et.al 
1999a; Shaw et.al 1999b).
4.2 NON-INVASIVE ASSESSMENT OF CORONARY ARTERY DISEASE
The principle behind all non-invasive tests for coronary artery disease is the same: to 
determine if there is adequate and homogeneous distribution o f coronary blood flow 
at rest and under conditions o f stress. Inadequate regional coronary flow may manifest 
as changes in the electrocardiogram, regional flow heterogeneity or regional wall 
thickening abnormalities. These in turn may be detected by surface 
electrocardiography, myocardial perfusion imaging and echocardiography, 
respectively. Figure 4.1 shows the sequence of events that occur in response to a 
reduction in regional myocardial blood flow (termed ischaemic cascade).
Exercise electrocardiography is the most commonly employed non-invasive test for 
the diagnosis o f coronary artery disease. Its advantages are that it is relatively
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Fig 4.1 Ischaemic cascade: Flow heterogeneity 
occurs earlier than other manifestations of reduced 
myocardial blood flow (Beller GA, 1995b).
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inexpensive, simple to perform and widely available. However, it has a relatively low 
sensitivity and specificity (average 68% and 77%, respectively) (Detrano et.al 1989), 
and cannot be applied in many patients for reasons including inability to perform 
adequate exercise (physical limitation, limiting non-cardiac symptoms) and 
confounding changes on the baseline electrocardiogram (left bundle branch block, left 
ventricular hypertrophy, digitalis therapy). Myocardial perfusion imaging and 
echocardiography, in conjunction with some form o f stress testing offers significantly 
improved diagnostic accuracy in comparison to exercise electrocardiography (Beller 
1995b). While left ventricular hypertrophy and left bundle branch may cause false 
positive results with myocardial perfusion imaging (Krishnan et.al 1993; Tubau et.al 
1989), echocardiography is limited in 5% to 10% of subjects by a suboptimal echo 
window. The average diagnostic accuracy o f both techniques for the detection of 
coronary artery disease is in the range o f 80% to 90% (Beller 1995b). Myocardial 
perfusion imaging offers a slightly higher sensitivity compared to stress 
echocardiography while the latter is slightly more specific (Quinones et.al 1992). 
Although myocardial perfusion imaging is associated with a small radiation dose to 
the patient (18 mSv from a thallium-201 and 8 mSv from a Tc-99m study), this is 
comparable to the radiation burden of coronary arteriography (10 mSv) (Johansson 
et.al 1992)
4.3 RATIONALE OF STRESS TESTING
Coronary vascular autoregulation maintains normal resting coronary blood flow until 
coronary stenosis approaches 80 to 90% (diameter) severity (Beller G 1995b; Gould 
et.al 1974; Lindner et.al 1995; Wilson 1996). Therefore, patients may be entirely 
asymptomatic and myocardial perfusion images may be entirely normal at rest even in
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the presence of a physiologically significant stenosis (Gould et.al 1974). However, 
when blood flow through such stenotic vessels is augmented either indirectly by the 
increased demands o f dynamic exercise, or directly by pharmacological means, flow 
heterogeneity is produced between normal and stenotic coronary vascular beds 
because of a relative regional impairment in flow augmentation or an altered 
coronary flow reserve (Botvinick et.al 1991; Cannon et.al 1987; Demer et.al 1990; 
Gould et.al 1978a; Gould 1978b; Kloclce 1987). Coronary flow reserve is impaired 
when stenosis severity approaches 50%, and therefore this is considered the level of 
stenosis that is physiologically significant (Fig 4.2).
In normal hearts much o f the autoregulation o f myocardial blood flow occurs by 
constriction or dilatation of the microcirculation (blood vessels < 400 pm in diameter) 
(Marcus et.al 1990). When there is a stenosis in a large epicardial artery, the 
microvasculature dilates in response to a drop in pressure across the stenosis. This 
autoregulation serves to maintain coronary capillary pressure within a narrow 
physiological range. Therefore, during stress, further increases in blood flow in these 
regions is restricted, resulting in a reduction in regional coronary flow reserve (Beller 
G 1995c; Canty et.al 1985). This will produce a relative reduction in regional flow in 
the stenotic beds compared with normal vascular beds, and may be detected as 
changes on the surface electrocardiogram, defects on myocardial perfusion imaging or 
regional wall thickening abnormality on echocardiography (Schelbert et.al 1982; 
Strauss et.al 1977). Therefore, coronary lesions which may be clinically silent at rest, 
may become evident and symptomatic after interventions that augment coronary flow. 
Thus it is possible to evaluate the coronary circulation by assessing its reactivity and
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ability to augment perfusion. This is the basis for stress testing in conjunction with 
non-invasive cardiac imaging.
Demonstration o f such a blunted coronary flow reserve actually defines a 
physiologically significant coronary lesion more accurately than the percent anatomic 
stenosis derived from coronary arteriography (Miller et.al 1994a; Pijls et.al 1996; 
Uren et.al 1994; Wilson 1996). Manifestation o f coronary hypoperfusion induced by 
interventions that augment coronary blood flow represent myocardium at risk related 
to a coronary stenosis, and provide a valid and useful non-invasive clinical definition 
o f lesion significance.
4.4 METHODS OF STRESS TESTING:
Stress testing may be performed by the following methods:
A) Dynamic exercise: Treadmill exercise
Bicycle exercise
B) Pharmacological stress:
Inotropic stress Dobutamine
Arbutamine
Vasodilator stress: Dipyridamole
Adenosine
C) Other techniques: Atrial pacing 
4.4a Dynamic exercise stress
Dynamic exercise is the most commonly used form of stress testing. Its advantages 
are that it is physiological, easily applicable, widely available and provides a 
quantitative assessment o f exercise capacity which has prognostic value (Morris et.al 
1991).
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However, approximately 15 to 20 percent o f patients referred for stress testing are 
unable to perform an adequate exercise protocol (Beller G 1995c; Iskandrian et.al 
1994). This may be related to several factors including general debility, lack of 
physical fitness, peripheral vascular or lung disease, arthritis, other systemic illness, 
fear or unfamiliarity with the exercise equipment. The haemodynamic response of 
some patients may be blunted by anti -anginal medication. Non-invasive imaging 
performed in patients who do not perform adequate exercise may be normal despite 
the presence o f significant coronary disease (Esquivel et.al 1989; Iskandrian et.al 
1989a). In such patients pharmacological stress presents a suitable alternative to 
dynamic exercise.
4.4b Pharmacological stress
Pharmacological stress agents can be classified into inotropic agents (dobutamine and 
arbutamine) that indirectly increase coronary blood flow by increasing myocardial 
oxygen consumption, and vasodilators (dipyridamole, adenosine) that directly 
augment myocardial blood flow by dilating the coronary micro vasculature. Inotropes 
increase myocardial blood flow two to three-fold, where as vasodilators increase flow 
three to five-fold (Heller 1996; Iskandrian et.al 1988; Leppo 1996). Based on the 
mechanism of action, vasodilators may be more suitable for myocardial perfusion 
imaging where as inotropic stress may be optimally suited for stress echocardiography 
(Geleijnse et.al 1995; Soman et.al 1997).
4.4c Vasodilator stress
The principle o f vasodilator stress myocardial perfusion imaging was first introduced 
by Strauss and Pitt in 1977. Currently available vasodilator stress agents are
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dipyridamole and adenosine. Dipyridamole was the agent used in this study and is 
therefore, described in detail.
4.5 DIPYRIDAMOLE STRESS 
4.5a The agent
Dipyridamole is a pyrimidopyrimidine compound with vasodilating and 
antithrombotic actions. It has a molecular weight o f 504, and is lipophilic and mildly 
acidic in solution. It is metabolised primarily in the liver and excreted in the bile. 
Therefore hepatic insufficiency could result in prolonged activity (Botvinick et.al 
1991; Heilsen-Kadsk et.al 1979)
4.5b Mechanism of action
Dipyridamole primarily inhibits cellular adenosine uptake. It also alters red cell 
membrane, inhibiting adenosine access to the activity o f membrane-bound adenosine 
deaminase, the enzyme primarily responsible for adenosine degradation, thus 
resulting in increased blood levels o f adenosine (Knabb et.al 1984; Sparks et.al 1986). 
Adenosine is a potent arteriolar dilator. It acts on the adenosine receptors. Activation 
of the Ai receptor results in slowing o f the heart rate and atrioventricular conduction, 
whereas the h i receptor mediates vasodilatation. An A3 receptor may mediate 
bronchospasm(Belardinelli et.al 1989). It has significant effects on the coronary 
resistance vessels, the arterioles and the precapillaries, resulting in a three to five -  
fold regional coronary flow augmentation in normal vessels (Elliot 1961; Feldman 
et.al 1981; Gould et.al 1974; Gould 1978a; Sorensen et.al 1985). This approaches the 
maximal vascular response or normal "coronary flow reserve” and exceeds the 
augmentation in coronary flow that can be brought about by dynamic exercise.
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Dipyridamole stress results in a mild decrease in systolic and diastolic blood pressure, 
mild increase in heart rate and cardiac output, but no significant change in myocardial 
oxygen consumption (Beller G 1995c).
4.5c Test Protocol
Patients must have nothing to eat for at least 4 hours before dipyridamole testing. This 
is in order to put the patient at metabolic baseline, and to prevent interfering 
gastrointestinal and other background flow. Caffeine or theophylline containing 
substances including coffee, coke, tea and aminophylline therapy, block endothelial 
adenosine receptors. All theophylline containing preparations are optimally withheld 
for 48 hours, but it is not necessary to discontinue oral dipyridamole or other 
medications. (Botvinick et.al 1991; Leppo 1996).
The standard dose o f dipyridamole is 0.14 mg/kg per minute infused for 4 minutes 
with constant haemodynamic and electrocardiographic monitoring. In the high dose 
protocol, an additional dose of 0.14 mg/kg for 2 minutes is infused 4 minutes after the 
initial dose. There is some evidence that the high dose protocol may increase the 
sensitivity for detection o f coronary artery disease (Lalonde et.al 1994), but animal 
studies have failed to show an advantage over the conventional dose in the degree of 
vasodilatation produced (Voudris et.al 1996).
Dipyridamole and elevated adenosine levels peak and plateau approximately 7 to 8 
minutes after infusion onset. (Lewin et.al 1984; Marchant et.al 1986; Mayes et.al 
1984; Okada et.al 1982a; Wilson et.al 1986). Radionuclide administration is therefore 
optimally performed 3 to 4 minutes after infusion termination. However, the
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vasodilatory peak o f adenosine remains at a plateau for 30 to 60 minutes, and 
therefore radionuclide administration can be delayed for several minutes without 
prejudicing test outcome. Tracer injection may be carried out earlier if intolerable 
patient symptoms occur. Hand-grip (Rossen et.al 1989)or low level exercise (Casale 
et.al 1988)have been suggested to accompany dipyridamole stress. Although this does 
not improve cardiac uptake o f the radionuclide tracer, it does improve the myocardial 
to non-cardiac count ratios o f the tracer (Pennell et.al 1994). Intravenous 
aminophylline, usually 75-100 mg up to 250 mg, may be given at least 3 to 4 minutes 
after tracer administration to abort side effects. Some authors have advocated the 
routine use of aminophylline after dipyridamole stress since it is safe, and prevents 
delayed side effects that may appear during imaging. However care must be taken not 
to abort the pharmacological effect o f dipyridamole with aminophylline before full 
extraction of the tracer agent.
4.5d Side effects and complications
Dipyridamole infusion is extremely safe and comparable with exercise testing (Beller 
1990; Lam et.al 1988). However, rare death and serious complications have been 
reported (Bayliss et.al 1983; Cushley et.al 1985; Lewin et.al 1987; Mann et.al 1985). 
Dipyridamole-induced side effects generally relate to induced peripheral vasodilatory 
effects and occur in roughly 50% to 60% of patients(Cushley et.al 1985; Mann et.al 
1985; Zhu et.al 1988) (Bayliss et.al 1983; Mann et.al 1985; Zhu et.al 1988). They are 
generally benign, o f low intensity, and often serve more as an indicator o f drug effect 
than as a warning o f impending complications. Chest pain, which appears in about 
20% of patients, seems to occur infrequently on an ischaemic basis, but may relate to 
direct, adenosine-mediated stimulation o f cardiac pain receptors, or even oesophageal
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spasm (Lagerquist et.al 1990; Pearlman et.al 1988; Sylven et.al 1986; Zhu et.al 1988). 
Although ST-segment depression also occurs infrequently, it is extremely specific for 
coronary disease and generally relates to advanced coronary stenosis. It may be 
caused by subendocardial ischaemia resulting from a steal mechanism (Chambers 
et.al 1988; Keltz et.al 1987). Occasionally it may be useful to give nitro-glycerine in 
addition to aminophylline to reverse ischaemia. Bradyarrhythmias and heart block, 
related to the direct blocking effects o f adenosine on the conduction system are rare. 
Bronchospasm is a rare complication that can be rapidly reversed with aminophylline, 
but the technique is contraindicated in patients with a history o f recent bronchospasm.
An oral dipyridamole protocol (Borges-Neto et.al 1988; Jain et.al 1990; Taillefer et.al 
1986)has also been proposed which employs 300 to 400mg crushed dipyridamole 
tablets in 30 ml o f water. Peak effect occurs in 45 minutes at which time the 
radionuclide is administered. However, absorption is erratic and gastrointestinal 
intolerance is frequent, making the technique difficult to justify when intravenous 
dipyridamole is available easily.
4.5e Diagnostic accuracy of dipyridamole perfusion scintigraphy
The average sensitivity and specificity o f dipyridamole perfusion scintigraphy 
demonstrated in early studies was 86% and 71% respectively (Beller 1991; Botvinick 
et.al 1991; Leppo 1989; Varma et.al 1989) comparable to perfusion scintigraphy in 
association with optimal exercise (Leppo 1989). However, these studies utilised 
planar imaging with Thallium-201 and the current SPECT imaging protocols using 
technetium ligands have improved both sensitivity and specificity to above 90%. In 
addition, owing to its near maximal effect on coronary flow reserve, dipyridamole
50
perfusion scintigraphy may be more sensitive than exercise for lesions o f marginal 
significance (Albro et.al 1978; Botvinick et.al 1991; Gould 1978b).
4.5f Assessment of prognosis
It is well established that dipyridamole stress perfusion imaging accurately rislc- 
stratifies patients referred for assessment o f known or suspected coronary artery 
disease, patients undergoing peripheral vascular surgery (Leppo et.al 1985) and post­
infarction patients (Brown et.al 1990). It is o f special importance in the preoperative 
assessment o f patients undergoing surgery for peripheral vascular disease who have 
restricted exercise capacities, and in whom the major perioperative risk is from 
coexistent coronary artery disease. The demonstration o f reversible perfusion defects 
in these patients is indicative o f high perioperative risk for adverse cardiac events, and 
revascularisation o f these patients improves their risk profile significantly (Leppo etal 
1985)
4.5g Disadvantages
Dipyridamole stress allows no assessment of the patient’s exercise capacity. Apart 
from being the most important prognostic variable among exercise parameters, the 
achieved exercise level and haemodynamic response may be related to physical 
activities and form a basis for rehabilitation and exercise prescription.
While the heart rate and blood pressure response provide a simple method to 
determine the adequacy o f dynamic exercise, the provocation o f symptoms and 
effects on peripheral haemodynamics is the only indirect indicator available of the
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adequacy o f dipyridamole infusion. However, this does seem to correlate well. 
(Botvinick et.al 1991)
The occurrence o f functional myocardial ischaemia during dipyridamole infusion has 
been documented, but its frequency is a subject o f controversy. It is postulated to 
occur due to a steal effect resulting in redistribution o f blood from the ischaemic 
subendocardium to the epicardium, or to reduced coronary perfusion pressure in 
presence o f full coronary dilatation and absent autoregulation. A number o f studies 
utilising PET perfusion techniques or echocardiography have suggested that the 
occurrence of ischaemia is not an invariable occurrence during dipyridamole stress 
and its use with techniques like echocardiography may be inappropriate (Becker 
1978; Gould 1989; Hansen et.al 1998; Wilcken et.al 1971).
4.5h Comparison with adenosine
Although adenosine and dipyridamole exert similar physiological effects on the 
coronary circulation, adenosine has an extremely short biological half life of 
approximately 4-10 seconds. Its effects and side-effects are therefore more short lived 
compared to dipyridamole. Accordingly, the injection o f radiotracer is performed 
during rather than after adenosine infusion, in contrast to the protocol adopted for 
dipyridamole stress testing (Iskandrian et.al 1994). Adenosine may also have a 
relatively greater coronary vasodilator potency in comparison to dipyridamole, but 
this does not appear to translate into a clinical benefit. The diagnostic accuracy o f the 
two agents for the diagnosis o f coronary artery disease is comparable (Beller 1995c; 
Iskandrian et.al 1994).
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CHAPTER 5
PERFUSION TRACERS USED IN 
NUCLEAR C A R D IO LO G Y AND THEIR  
M Y O C A R D IA L  KINETICS
5.1 CHARACTERISTICS OF AN IDEAL TRACER
An ideal tracer for the assessment o f myocardial perfusion should be taken up by the 
myocardium in linear proportion to blood flow across the entire range o f myocardial 
blood flows attainable in humans (maximum 8-fold increase) (Heller 1996). It should 
be efficiently extracted from blood during its first pass through the coronary 
circulation, retained in stable distribution during data acquisition, have favourable 
myocardial to non-cardiac tissue ratio and its uptake by the myocardium should be 
minimally affected by cellular metabolic alterations. It should have optimal imaging 
characteristics including a high photon flux, energy between 100 and 200 keV and a 
short half-life resulting in low radiation burden to the patient. And finally it should be 
easily available with competitive pricing (Table 5.1).
No currently available tracer possesses all these properties.
5.2 THALLIUM-201
Thallium-201 was the first radionuclide to be used widely as a myocardial perfusion 
agent. It was introduced in the early 1970s and, until recently, was the most popular 
myocardial perfusion tracer. Thallium-201 is transported across the myocyte 
membrane actively by the Na/K ATPase pump, although significant amounts may 
also diffusely passively across the electrochemical gradient (McCall et.al 1985; 
Weich et.al 1977). Approximately 5% of the injected dose is concentrated in the 
myocardium and the first pass myocardial extraction fraction is high (88%±2.1%). 
Uptake into the myocardium peaks in 10 minutes, and undergoes significant 
redistribution so that imaging should be completed within a maximum o f 30 minutes /  
(De Koclc et.al 1986; Hamilton et.al 1978; Weich et.al 1977).
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, ,
Ideal radioDharmaceutical Thallium-201 Tc-99m Ligands
Distribution in proportion to 
blood flow Yes Yes
100% myocardial extraction 
at rest 80% Variable 50%-90%
Suitable energy for imaging 
(100-200keV) Less favourable Yes
High myocardial: 
background ratio Sub-optimal (lungs)
Sub-optimal
(hepatobilary)
Retained in myocardium long 
enough to obtain good 
quality images
Sub-optimal because 
o f redistribution
Yes
Clinically significant 
redistribution absent
Suitable physical half-life 
and patient dosimetry
No
(less favourable)
Yes
Favourable
Quantification Yes Yes
Table 5.1 Tracer Characteristics
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The principal emission (88%) of thallium-201 comprises o f mercury X-rays with 
photon energies o f 69-80keV. These are suboptimal for gamma cameras imaging, and 
are subject to significant attenuation as they traverse the body tissues during imaging 
(Mueller et.al 1976). Only 12% of its emissions are gamma-rays with photo peaks at 
135 and 167 lceV. It has a long half-life o f 72 hours, which results in a high radiation 
dose to the patient and limits the amount o f tracer that can be safety administered 
(Atkins et.al 1977). The effective total body dose equivalent of thallium-201 is 0.23 
mSv/MBq. The dose limit for a single administered dose is 80 MBq, resulting in a 
radiation dose o f 18mSv (Pennell et.al 1995). There is significant uptake o f thallium- 
201 by lungs, up to 15% in normal volunteers significantly increased in patients with 
heart failure, which could cause interfering background activity (Lebowitz et.al 1975; 
Mueller et.al 1976). Finally, being cyclotron-produced limits the availability o f this 
agent and makes it relatively expensive.
The advantages o f thallium-201 include its high myocardial first pass extraction 
fraction, the property o f redistribution, which makes it suitable for the detection of 
myocardial viability, and lung uptake, which has been established as a strong 
prognostic indicator in patients with left ventricular dysfunction (Gill et.al 1987; 
Kaul et.al 1988a).
5.3 TECHNETIUM 99m -LABELLED TRACERS
The physical properties o f technetium -99m (Tc-99m) are better suited for gamma 
camera imaging. The 1401ceV photon energy o f the gamma radiation produces higher 
quality images and permits sufficient count acquisition to permit ECG-gating of 
images, and the shorter half life o f 6 hours provides better patient dosimetry, making
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it possible to administer 10 to 15 times the thallium-201 dose to yield better images in 
a shorter time (Beller 1995a). The effective dose of 1000 MBq, the recommended 
dose for a single-day rest stress protocol, is approximately 8 mSv (Pennell et.al 1995). 
Technetium -99m can be easily eluted from a generator at all times ensuring easy 
availability on-site. The Tc-99m-labeled tracer introduced initially were Tc-99m 
tertiary butylisonitrile (TBI) (Holman et.al 1984; Sia et.al 1986) and Tc-99m 
carbomethoxyisopropyl isonitrile. The usefulness o f both these agents was hampered 
by unfavourable heart to background activity. Another agent Tc-99m teboroxime had 
an excellent myocardial first pass extraction fraction, but rapid washout from the 
myocardium made it impossible to use clinically (Leppo et.al 1990; Seldin et.al 1989; 
Stewart et.al 1990). The two Tc-99m-labeled tracers that have gained wide popularity 
for clinical use are Tc-99m sestamibi and Tc-99m tetrofosmin.
5.3a Tc-99m sestamibi
Tc-99m -hexakis-2-methoxy-2-methylpropylisonitrile (Tc-99m sestamibi) is a 
lipophillic compound that distributes in the myocardium in proportion to myocardial 
blood flow. The first pass myocardial extraction fraction is less than that o f thallium- 
201 (68.3% ± 4.3%) and approximately 1% is localised in the heart (Meerdink et.al 
1990b). It diffuses across the myocyte membrane along an electrochemical gradient, 
but is then sequestered in the mitochondria by the large negative transmembrane 
potentials (Piwnica-Worms et.al 1990). This process does not occur in irreversibly 
damaged cells and therefore, Tc-99m sestamibi uptake and retention indicates cellular 
viability. There is no clinically significant redistribution (10-15%) o f this agent in the 
myocardium and therefore, imaging can be performed for up to 4 hours after tracer 
injection.(Maddahi et.al 1990) Interventions that slowly deplete myocyte substrate,
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enzymes or ATP stores do not affect Tc-99m sestamibi uptake until irreversible 
cellular injury has occurred (Piwnica-Worms et.al 1990). Similarly, the extraction of 
Tc-99m sestamibi is not significantly altered by commonly used cardiac 
pharmaceutical agents (Mousa et.al 1991). The agent is available commercially 
(Cardiolite™ by DuPont Pharma) as a freeze dried product and can be easily labelled 
with Tc-99m eluted from a generator. This procedure is described in detail in the 
section on methodology.
The disadvantages o f Tc-99m sestamibi include the lower myocardial first-pass 
extraction fraction (68.3 %± 4.7%) and prominent liver, gall bladder and gut activity. 
The latter may be reduced by giving patients a fatty meal prior to imaging. There is no 
significant uptake of this tracer by the lungs, and therefore the prognostic information 
afforded by measuring lung uptake during thallium-201 imaging is not available with 
Tc-99m sestamibi.
5.3b Tc-99m tetrofosmin
Tc-99m l,2-bis[bis(2-ethoxyethyl)phosphino]ethane (Tc-99m tetrofosmin) (Kelly 
et.al 1993) is a diphosphine compound that is available for commercial use as a 
freeze-dried product (Myoview™ by Amersham Healthcare). It has imaging 
properties similar to Tc-99m sestamibi and is also distributed in the myocardium in 
proportion to regional blood flow. However, it has a lower first pass myocardial 
extraction fraction (54%±3.7%). It may undergo earlier hepatic clearance than Tc- 
99m sestamibi thus enabling earlier imaging with less interference from liver and gut 
activity (Higgley et.al 1993; Kelly et.al 1993).
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5.4 TE C H N IQ U E S  TO S TU D Y  TRACER K IN E T IC S  
5.4a Whole animal models
Whole animal models (anaesthetised porcine and canine models) have been 
conventionally used to study the initial myocardial distribution o f a perfusion tracer 
and the corresponding regional myocardial blood flow. A range o f myocardial blood 
flows can be obtained by coronary occlusion and pharmacological vasodilatation 
(Glover et.al 1990a). Blood flow is quantitated by injecting radiolabelled 
microspheres into the left atrium, and withdrawing an arterial sample at a fixed rate 
into a syringe concurrently. Microspheres are not extracted by the myocardium and 
therefore, function as pure flow tracers. A small fraction (<0.1 %) o f them get trapped 
in the myocardial precapillary arterioles, in proportion to the regional blood flow. The 
animals are then sacrificed, the heart is sectioned and the microsphere activity per 
gram of myocardial tissue is counted in a well counter. Since the product o f 
microsphere concentration and the flow rate in the syringe should be equal to the 
product o f microsphere activity and flow rate in the myocardial sample, the 
myocardial blood flow rate can be calculated (Heymann et.al 1977). If a perfusion 
tracer is injected simultaneously, the relationship between myocardial tracer activity 
per gram of myocardial tissue to the corresponding blood flow per gram of 
myocardium can be assessed. In an open chested model, tracer activity in the 
myocardium can be monitored continuously with either external or directly implanted 
scintillation counters, or from biopsy samples taken at various times following tracer 
injection (Gerson M et.al 1997). Therefore the subsequent kinetic properties of the 
tracer over time can also be characterised
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The isolated rodent or rabbit heart preparation is used to accurately assess extraction 
fraction o f a myocardial perfusion tracer (Meerdink et.al 1990a). An example is the 
Langendorrf preparation where the isolated heart is suspended on a stand and perfused 
retrograde through the aorta at constant flow or pressure. For studies o f tracer 
kinetics, the constant flow model is usually used.
The isolated perfused heart provides a number of advantages for measurement of 
tracer kinetics compared to whole animal models. Physiologic parameters including 
coronary flow, cardiac work (paced heart rate), substrate availability and drug 
delivery can be controlled independently. This allows the effects o f coronary blood 
flow and cellular viability on the myocardial extraction o f tracer to be assessed 
independently. The coronary venous effluent can be assessed to determine tracer 
extraction or the tracer residue may be directly monitored with external radiation 
detectors (Bassingthwaighte et.al 1976).
Extraction fraction o f a diffusible tracer is determined by the multiple tracer indicator- 
dilution technique wherein an intravascular reference tracer like In11 ^ labeled albumin 
(which does not leave the coronary vascular space) is injected simultaneously with 
one or more perfusion tracers. The extraction fraction o f the tracer can be determined 
by comparing the amount of each diffusible tracer with that o f the reference tracer in 
timed samples of cardiac effluent.
The transport function, h (t), describes the fraction of injected tracer transported 
through the coronary circulation and recovered in the effluent per second. The
5.4b Isolated perfused heart models
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instantaneous extraction o f any tracer at each time point can be determined by the 
difference between the transport function o f the reference tracer and the diffusible 
tracer. The maximum extraction fraction, Emax, is the largest fraction of tracer 
extracted. The net extraction, Enet, is the cumulative fraction o f the tracer injected that 
is retained by the myocardium (Gerson M et.al 1997).
5.4c Isolated myocyte models
Unlike whole animal and isolated heart models, suspensions or cultures of isolated 
cardiac myocytes can be used to study net uptake and retention o f tracers independent 
of myocardial blood flow (Gerson M et.al 1997).
In this way flow-independent tracer uptake may be plotted for multiple tracer 
concentrations in the medium and the effects o f specific drugs or interventions may 
also be studied. Popular models for isolated cardiac myocytes include ventricular cells 
from 10-day old chick embryos and adult rat ventricular cardiocytes in a suspension 
medium.
5.5 MYOCARDIAL KINETICS OF CURRENTLY AVAILABLE TRACERS
The sensitivity o f a perfusion tracer to detect coronary artery disease and reversible 
ischaemia by myocardial perfusion imaging depends on its ability to track regional 
differences in myocardial blood flow. The flow heterogeneity between normal and 
abnormal coronary vascular beds is then represented as a perfusion defect on 
scintigraphy.
Diffusible tracers that are used to assess myocardial blood flow are generally taken up 
by the myocardium in proportion to regional blood flow (Dahlberg et.al 1999; Heller
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1996; Watson et.al 1999). The net amount o f tracer taken up by the myocardium at 
any time depends on several factors. Firstly, the tracer has to be delivered to the 
capillary-myocyte interface; a process which is flow dependent so those regions 
supplied by stenosed coronary arteries would receive relatively less tracer. The second 
step involves the transport o f the tracer across the myocyte membrane by active 
(thallium-201) or passive (technetium ligands) processes and the retention o f the 
tracer in the myocyte. And finally, some of the tracer diffuses back out o f the myocyte 
into the capillary circulation. • Therefore the amount o f tracer activity measurable in 
the myocardium is the net effect of all these processes. It also follows that tracer 
deposition in the myocardium requires both coronary flow and cellular viability.
An ideal perfusion tracer would be taken up by the myocardium in proportion to 
blood flow across the entire range o f myocardial blood flow rates attainable under 
physiological, pathological and stress-induced hyperaemic conditions. However, this 
linear relationship between blood flow and tracer uptake is limited at both ends o f the 
spectrum o f myocardial blood flows. At low flows, the transit o f tracer molecules 
through the myocardial capillaries is slower, resulting in greater extraction o f the 
tracer. Also, tracer that has diffused back into the capillary circulation has a greater 
chance o f being taken up again by the myocardium. Therefore, at low flows, tracer 
activity overestimates myocardial blood flow. At high flow rates, tracer uptake is 
limited primarily by the myocardial extraction fraction, but also by faster capillary 
transit. As myocardial blood flow is progressively increased, there comes a point 
beyond which there is no increase in the myocardial uptake o f the tracer despite 
further increases in blood flow, a phenomenon called “roll-off’ . The precise blood 
flow rate at which this plateau of tracer uptake occurs depends on the first -pass
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myocardial extraction fraction o f the tracer (Fig 5.1). Hence, in animal studies by 
Gray and Gewirtz (1991) Tc-99m teboroxime uptake, with its high myocardial 
extraction (E max 0.72+0.09), paralleled blood flow rates o f up to 5 ml/gm/min. 
Nielsen et al (1980b) demonstrated linear increases in thallium-201 uptake (Emax
0.59-0.73) with flow rates up to 3ml/gm/min. Studies by Olcada et al (1982a)and 
Glover et al (1990b) suggest that the uptake o f Tc-99m sestamibi (E max 0.31-0.73) 
reaches a plateau at 2ml/gm/min. In comparison to Tc-99m sestamibi, Tc-99m 
tetrofosmin has a lower extraction fraction (E max 0.24+0.09) and its myocardial 
uptake may plateau when blood flow increases approximately 1.5 fold (Glover et.al 
1990b; Heller 1996; Sinusas et.al 1994).
The roll-off phenomenon has more than just theoretical relevance. It limits the amount 
o f tracer that can be taken up by the myocardium perfused by the normal coronary 
vessels, especially during hyperaemic flow, and thereby reduces the contrast between 
normal and abnormally perfused myocardium (Fig 5.2). This could result in a 
decreased sensitivity for the detection o f coronary artery disease and reversible 
perfusion defects, and also result in perfusion defects o f lesser extent and severity. 
Perfusion tracers with a low extraction fraction are especially likely to roll off during 
the high myocardial blood flow rates encountered during vasodilator stress, and a 
reduced defect contrast is more likely to affect the detection o f minor flow 
heterogeneity resulting from mild to moderate rather than severe coronary artery 
disease.
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The effect o f a low myocardial extraction fraction has been demonstrated in several 
animal and clinical studies comparing thallium-201 with one o f the technetium- 
labelled tracers. Glover et al (1995) demonstrated that Tc-99m sestamibi 
underestimated the flow disparity between normal and stenotic coronary beds more 
than thallium-201 under conditions o f mild and critical LAD stenosis. In clinical 
studies, Narahara et al (1990) and Maublant et al (1992) demonstrated smaller defect 
size with Tc-99m sestamibi compared to thallium-201 in patients undergoing exercise 
perfusion imaging. Similarly, Matsunari et al (1996) and Tamalci et al (1994) have 
demonstrated smaller perfusion defects on exercise Tc-99m tetrofosmin imaging 
compared to thallium-201 in patients with coronary artery disease. Nakajima et al 
(1993) and the phase III multicentre tetrofosmin trial (Zaret et.al 1995) reported 
improved detection o f reversible ischaemia with thallium-201 compared to Tc-99m 
tetrofosmin. These studies are discussed in more detail later on.
This biokinetic advantage o f thallium-201 is at least partially offset by its inferior 
physical properties for perfusion scintigraphy. Of more relevance is the lower 
extraction fraction o f Tc-99m tetrofosmin compared to Tc-99m sestamibi, and these 
agents have not been previously compared in a clinical trial with a sufficient number 
of patients undergoing imaging with both agents. Furthermore, previous studies have 
included patients with severe coronary artery disease and, previous myocardial 
infarction and not ensured maximal myocardial blood flow levels by their choice of 
stress modality.
In the current study, Tc-99m sestamibi and Tc-99m tetrofosmin were compared in a 
specific group o f patients with angiographically proven mild to moderate coronary
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artery disease using high dose dipyridamole stress. The choice o f patients and the 
study design provided the optimum conditions for differences in tracer sensitivity 
arising as a result o f differing myocardial extraction fractions to manifest.
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CHAPTER 6
R ATIO N ALE AND OBJECTIVES  
OF THE STUDY
As discussed in the previous chapter, animal studies have shown that Tc-99m 
tetrofosmin has a slightly lower myocardial extraction fraction compared to Tc-99m 
sestamibi, and its uptake by the myocardium plateaus at lower myocardial blood flow 
rates. Whether this lower myocardial extraction fraction and the consequently lower 
defect contrast in images produced by Tc-99m tetrofosmin results in underestimation 
o f perfusion defects has not been established unequivocally. Two small studies 
(Flamen et.al 1995), (Acampa et.al 1998)have made direct comparisons o f the two 
agents in the same group of patients and demonstrated no difference in diagnostic 
sensitivity, detection of reversible perfusion defects or image quality. However, 
differences occurring as a result o f a low myocardial extraction fraction are most 
likely to manifest in the setting o f mild to moderate (as opposed to severe) coronary 
artery disease where the contrast between normal and abnormal myocardium is 
inherently low, and with the use o f vasodilator stress where the high myocardial blood 
flow rates achieved make tracer roll off more likely. Therefore, patient selection and 
protocol design may have masked differences between the two agents in these 
studies.
With significant advantages over thallium-201, Tc-99m sestamibi and Tc-99m 
tetrofosmin are the most commonly used perfusion tracers for myocardial perfusion 
imaging. Any difference in their ability to detect coronary artery disease or reversible 
perfusion defects is likely to have significant implications for the practice o f nuclear 
cardiology.
6.1 RATIONALE OF THE STUDY
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assessment of mild to moderate coronary artery disease by dipyridamole stress single
photon emission computerised tomography (SPECT) imaging by comparing
1. The ability of these tracers to detect reversible perfusion defects.
2. The extent o f perfusion abnormalities demonstrated by the two agents as 
determined by quantitative SPECT imaging.
3. The severity o f perfusion abnormality demonstrated by the two agents by 
quantitative SPECT imaging.
4. The concordance between the tracers for categorising myocardial segments into 
normal and abnormal segments, and the latter further into fixed and reversible 
defects.
5. The diagnostic accuracy o f the two tracers for detection o f disease.
6. The ability o f the two agents to detect coronary artery disease in individual 
coronary artery territories.
6.2 OBJECTIVES
This study aims to compare Tc-99m sestamibi and Tc-99m tetrofosmin for the
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CHAPTER 7 
M E T H O D O L O G Y
7.1 STUDY DESIGN
A total o f 81 patients with known coronary artery disease and 7 with low probability 
o f coronary artery disease were recruited into this study.
The study was conducted at two centres: Department o f Cardiovascular Medicine, 
Northwick Park Hospital, UK and the Department o f Nuclear Medicine, Hotel Dieu- 
de Montreal, Canada.
Patients who had recent coronary arteriography and fulfilled the inclusion criteria, and 
subjects with <5% probability of coronary artery disease and volunteered to 
participate, were recruited. Dipyridamole stress Single-Photon Emission Computed 
Tomographic (SPECT) imaging with Tc-99m sestamibi and Tc-99m tetrofosmin were 
performed in random order within 2 weeks o f each other and 2 months o f coronary 
arteriography.
Images were read by a panel o f two experienced and independent nuclear 
cardiologists who were not affiliated to either study centre. They were blinded to the 
clinical details o f the patients and the identity of the tracer. The Tc-99m sestamibi and 
Tc-99m tetrofosmin images were read separately, in random order.
Images were analysed visually (semi-quantitative) and quantitatively using the 
CEqual programme. For the subgroup o f patients recruited at the UK centre, a second 
internal reading o f images was undertaken, and quantitative analysis o f the scans was 
performed using the Liege quantitative programme.
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Fig 7.1 Study Design
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7.2 PATIENT SELECTION
7.2a Inclusion Criteria
1. Patients with 50 -90% stenosis of one or two major epicardial coronary arteries on 
qualitative coronary arteriography performed within two months prior to the study.
OR
Subjects with less than 5% pre-test probability o f coronary artery disease: Those 
who had no evidence o f coronary artery disease clinically, and with no history of 
hypertension, diabetes mellitus, premature coronary artery disease in first degree 
relatives or smoking. They were requested to volunteer for the study
2. Patients o f either sex aged >18 years
3. Provided informed consent prior to participation.
7.2b Exclusion Criteria
1. Severe coronary disease as indicated by the presence of any o f the following:
• >90% stenosis in any coronary artery by arteriography
• triple vessel disease
• left main stem disease
2. Previous myocardial infarction confirmed by significant elevation in cardiac 
enzymes or significant Q waves on the resting electrocardiogram.
3. Previous coronary revascularisation by percutaneous transluminal coronary 
angioplasty or coronary artery bypass grafting.
4. Left bundle branch block
5. Clinically unstable coronary artery disease
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6. Contraindications to dipyridamole stress:
• Bronchial asthma requiring therapy
• Atrioventricular node conduction abnormality of greater than first degree.
• Hypersensitivity to dipyridamole.
7. Significant valvular heart disease, heart failure (NYHA II to IV) or severe 
hypertension (resting systolic blood pressure >200 mmHg or resting diastolic 
blood pressure >180 mmHg)
8. Women of child bearing potential
9. Other significant concurrent illness.
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Approval for the study in the United Kingdom was obtained from the local ethical 
committee (Harrow Health Authority Ethical Committee) and the administration of 
Radioactive substances Advisory committee (ARSAC) of the Department of Health 
(UK). In Canada, the study was approved by the Institutional Review Board (IRB).
The study was conducted over an 18 month period at both centres.
7.3 E T H IC S  A P P R O V A L
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7.4 CORONARY ARTERIOGRAPHY
Patients were admitted to hospital on the morning of the procedure. Patients gave 
informed consent to undergo the procedure. The groin was prepared by removing the 
pubic hair.
Patients were positioned on the fluoroscopic table; the right groin was painted with 
Betadine solution and draped with sterile towels. An intradermal wheal of 1% 
lignocaine was raised slowly over the pulsation of the right femoral artery using a 26- 
gauge needle. Skin puncture was made over the femoral artery using the tip of a 
scalpel blade and further infiltration of deeper tissues with 1% lignocaine was carried 
out.
The femoral artery was canulated by the Seldinger technique. A 6- French sheath was 
introduced. The sheath was aspirated, flushed and connected by its side arm to a 
manifold for monitoring arterial pressure. A pigtail left heart catheter was then 
flushed and loaded with a 145 cm J-guide wire and introduced into the back bleed 
valve of the sheath. The soft end of the guide wire was then advanced carefully 
through the catheter to the level of the diaphragm before the catheter itself was 
advanced. The guide wire was then removed and the catheter was connected to the 
arterial manifold and double flushed with heparinised saline. Pressures from the 
ascending aorta and left ventricle was recorded. Left ventriculography was performed 
by injection of contrast from a power injector. Continuous fluoroscopic monitoring 
and recording of results on digital equipment were carried out in the 30° to 45° right 
anterior oblique projection.
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At the end of ventriculography, the pigtail catheter was withdrawn, and the sheath 
was immediately double flushed. A Judkins’ coronary catheter with end-hole design 
was used for cannulation of the left and right coronary arteries. The catheter was 
advanced to the aortic arch with the guide wire in place. The guide wire was then 
removed, and the catheter was attached to a specially designed manifold system 
which permitted the maintenance of a closed system during pressure monitoring, 
catheter flushing, and contrast agent administration. Left and right coronary ostia 
were intubated using standard manoeuvres and images acquired in standard 
projections.
After the procedure the femoral sheath was removed and haemostasis achieved by 
finger pressure.
7.5 PATIENT RECRUITMENT
Patients with coronary artery disease were recruited from the cardiac catheter 
laboratory if their coronary anatomy was deemed to fit the inclusion criteria for the 
study. Patients in the low probability group were selected based on demographic 
characters, history and physical examination.
All patients were specifically requested to volunteer for the study.
7.6 PROTOCOL
After informed consent was obtained all patients underwent dipyridamole stress 
SPECT imaging with Tc-99m sestamibi and Tc-99m tetrofosmin in random order 
within 2 weeks of each other. A two-day (UK centre) or same-day (Canadian centre) 
rest-stress protocol was used. Within each centre individual patients were subjected to 
the same protocol for imaging with Tc-99m sestamibi and Tc-99m tetrofosmin.
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Perfusion imaging was performed within two months of coronary arteriography and 
patients were required to be clinically stable during this period, with no change in 
their anti-ischaemic medication, The decision to perform coronary arteriography was 
never influenced by results of perfusion imaging as the former always preceded the 
latter. This ensured that there was no referral bias.
7.7 PREPARATION OF THE RADIOTRACERS:
7.7a Tc-99m sestamibi was prepared by adding technetium-99m pertechnetate to 
commercially available vials of lyophilised kit formulation (Cardiolite™). Each vial 
of the product contains the following:
• 1 mg Cu(MIBI)4BF4 where MIBI=2-methoxy isobutyl isonitrile
• 0.075 mg Stannous chloride dihydrate
• 1 mg L-cysteine hydrochloride monohydrate
• 2.6mg sodium citrate dihydrate
• 20 mg mannitol
The contents of the vial are lyophilised and packaged under a nitrogen atmosphere. 
Prior to lyophilization the pH is 5.3-5.9.
The product was prepared under strict sterile and radiation protected conditions. 1-3 
ml of Tc-99m sodium pertechnetate in saline (maximum activity of 550GBq) were 
added to the vial and the contents mixed by swirling for a few seconds. Care was 
taken to withdraw a volume of gas from the vial equal to the volume of eluate added 
to normalise the pressure inside the vial. The vial was then placed in a shielded water 
bath and boiled for 10 minutes followed by cooling to room temperature. This process
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of heating and cooling can be hastened by currently available commercial equipment. 
The product must be used within 6 hours of preparation.
7.7b Tc-99m tetrofosmin
The kit for formulation of Tc-99m tetrofosmin (Myoview™) is a lyophilised product 
containing the following:
• 0.23 mg tetrofosmin
• 0.03 mg stannous chloride dihydrate
• 0.32 mg disodium sulphosalicylate
• 1.0 mg sodium D-gluconate
• 1.8 mg sodium hydrogen carbonate.
Four to 8 ml of Tc-99m sodium pertechnetate were added to the vial and incubated at 
room temperature for 15 minutes. Care was taken to withdraw a volume of gas from 
the vial equal to the volume of eluate added to normalise the pressure inside the vial. 
The Tc-99m sodium pertechnetate solution used should contain less than 5ppm 
aluminium, and the concentration must not exceed 1.1 GBq/ml. The pH of the 
prepared injection is in the range of 7.5 -9.0. Satisfactory radiochemical purity is 
achieved when Tc-99m tetrofosmin is reconstituted with Tc-99m sodium 
pertechnetate eluted up to 6 hours previously from a generator last eluted within 72 
hours. The product must be used within 8 hours of preparation.
7.8 RADIOCHEMICAL PURITY ASSESSMENT
The radiochemical purity of both Tc-99m sestamibi and Tc-99m tetrofosmin was 
checked before administration to the patient. The products were not used if 
radiochemical purity was less than 90%,
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Radiochemical purity is assessed using Baker-Flex aluminium oxide plates and 
ethanol.
Ethanol is poured into a beaker to a depth of 3-4mm, covered and allowed to 
equilibrate for approximately 10 minutes.
A drop of ethanol is placed on the aluminium oxide TLC paper approximately 1.5 cm
from the bottom end. A drop of the Tc-99m sestamibi solution is placed on the drop
of ethanol before the latter has dried. The plate is then placed in the beaker and
allowed to develop to a distance of 5 cm from the spot. After which it is cut through
the centre. Each piece is then measured in a dose calibrator.
Radiochemical purity is calculated by the following formula:
% Tc-99m sestamibi = Activity top portion x 100 
Activity both pieces
7.8b Tc-99m tetrofosmin
A similar procedure is used with a 35:65 acetone: dichloromethane mixture as solvent 
and ITLC/SG strip as TLC plate. The strip is marked at 3 cm from the bottom end (the 
origin, at which the sample is to be applied) and at 3 cm and 12 cm form the origin, 
which are the cutting points. A 10-20 microlitre sample is applied at the origin and 
chromatography performed. The strip is then cut into 3 pieces and the radiochemical 
purity is calculated by
% Tc-99m tetrofosmin Activity of the centre piece x 100
Total activity of all 3 pieces
7.8a T c-99m  sestam ibi
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7.9 DOSING
Doses were ordered from the Medical Physics laboratory the day before the scans. 
Doses were prepared and referenced for 09.00 hrs. The required quantities were 
withdrawn after correction for decay just before the procedure and measured in a 
counter prior to injection.
7.10 BLINDING OF THE IDENTITY OF THE TRACER
Tracer identity was unknown to the investigator performing the study. The codes were 
maintained by the technologist who withdrew the doses prior to administration, and 
broken only at the time of data analysis.
7.11 DIPYRIDAMOLE STRESS
Patients were requested to abstain from caffeine containing drinks and methylxanthine 
drugs for 24 hours before the study, and to have only a light breakfast on the morning 
of the study. Soon after their arrival in the laboratory, their weight was measured 
wearing light clothing and no footwear. After insertion of an intravenous cannula, a 
resting 12-lead electrocardiogram was obtained. Subsequently, a 12-lead 
electrocardiogram was monitored throughout the procedure and recorded every 3 
minutes. Blood pressure and heart rate were measured at baseline and every 3 minutes 
during the procedure.
Dipyridamole (0.56 mg/kg) was infused over 4 minutes followed 4 minutes later by
0.28 mg/kg over 2 minutes. Patients who developed severe symptoms after the initial 
dose were not given the second dose. The same dose of dipyridamole was used for
80
Tc-99m sestamibi and Tc-99m tetrofosmin imaging in a given patient. The perfusion 
tracer was injected as a bolus 2 minutes after completion of the infusion. When 
necessary, intolerable symptoms were reversed with 50 to lOOmg of intravenous 
aminophylline, given at least 5 minutes after administration of the tracer agent.
7.12 ELECTROCARDIOGRAPHY
The electrocardiogram was recorded as a 25:1 time- compressed record by displaying 
the template of the normal cardiac cycle at a rate of 1 mm/sec. The location of the PR 
segment was selected as a reference point and the J-point was marked automatically 
by vertical markers on the op of each lead complex, permitting visual validation.
7.13 BLOOD PRESSURE
Blood pressure was measured manually by a mercury-in-glass sphygmomanometer at 
the specified intervals and recorded.
7.14 SPECT IMAGING 
7.14a Equipment
SPECT imaging was performed on a dual headed camera (Sophycamera DST, Sopha 
Medical Vision, France). Each head contained a 1/2-inch thick Sodium iodide (Nal) 
crystal doped with thallium and shielded with lead, and 58 high performance 
photomultiplier tubes (50 hexagonal and 8 circular). The camera performance and 
data acquisition were controlled by a computer (SOPHA DST). The camera was 
equipped with a parallel hole, high resolution collimator.
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For the two-day protocol, 600 MBq was injected for both the stress and rest studies. 
In the one-day protocol, rest images were initially performed with 370 MBq of tracer 
followed 4 hours later by the stress study with 1110 MBq of tracer.
7.14c Data acquisition
Patients were provided with a glass of milk 10 to 15 minutes after tracer injection to 
facilitate gall bladder emptying and asked to drink several glasses of water before the 
scan. Women had their breasts strapped down with crepe bandages to minimise 
attenuation artefacts. The camera’s detector was set at 140 keV focused at the 
photopeak of Tc-99m sestamibi and Tc-99m tetrofosmin with an energy window of 
20%. Imaging was commenced 60 minutes after injection of the tracer with the 
patients lying supine. Images were acquired in 32 frames (40 second per frame) over 
a 180 arc from the 45 right anterior oblique to 45° left posterior oblique positions.
7.14d Image reconstruction
Images were reconstructed by back projection using a Butterworth filter (order 4, cut 
off 0.25). Transverse slices were reoriented into horizontal long axis, vertical long 
axis and short axis slices. Stress and rest images were displayed side by side.
7.14b D ose o f  radiotracers
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The SPECT images were analysed by two independent and experienced nuclear 
cardiologists who were not affiliated to either study centre. Both were blinded to the 
patient’s clinical details and the identity of the perfusion tracer. After masking of 
patient names, the stress and rest images were displayed side-by-side, and interpreted 
simultaneously. Differences of opinion were resolved by consensus. The Tc-99m 
sestamibi and Tc-99m tetrofosmin images of any given patients were not read 
consecutively.
For analysis, the left ventricle was divided into 17 segments on 3 short axes and 1 
vertical long axis slices. Each segment was then graded according to perfusion using a 
semi-quantitative, 4-point system (1 = normal, 2 = mildly reduced, 3=severely 
reduced, 4=absent) and classified as normal, reversible (new or worsening stress 
defect) or fixed (identical stress and rest defects). The overall image quality was 
assigned one of four grades (excellent, good, fair, poor) based on count density, 
myocardial and left ventricular cavity definition, and adjacent interfering visceral 
activity.
7.14f Quantitative Analysis
Two different quantitative parameters were used to define the myocardial perfusion 
defects:
1. The extent of defect: The extent of defect was quantified as a percentage of the 
entire myocardium involved. CEqual software was utilised for this calculation.
7.14e Im age interpretation and analysis
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2. Severity of defect: The defect/normal wall activity ratio was used to calculate the 
severity of defect and was determined in two groups of patients, those in whom Tc- 
99m sestamibi and Tc-99m tetrofosmin detected reversible perfusion defects in 
identical segments, and those in whom such defects were demonstrated by only 
one of these agents or by both in different myocardial segments. For this analysis, 
four short axis slices were summed taking care to choose identical slices from Tc- 
99m sestamibi and Tc-99m tetrofosmin images of any given patient. Regions of 
interest were then placed manually on the area of defect and the area of the 
myocardium with the maximum tracer uptake. By determining the count densities 
within the defect and normal regions of interest for each defect, a mean 
defect/normal count density ratio was computed. The average of three values was 
taken.
7.14g CEqual quantitative analysis of defect extent and severity
The CEqual (Cedars-Emory quantitative analysis) is a quantitative program developed 
jointly at Emory University and Cedars-Sinai Medical Centre and is based on a 
database approach for quantifying myocardial perfusion in which the patients 
perfusion abnormalities are compared with a database of previously defined lower 
limits of normal (Kang et.al 1997). The three -  dimensional sampling method used 
provides a method of extracting the three-dimensional myocardial count distribution 
(Garcia et.al 1990). The technique uses spherical co-ordinates to sample the apical 
region and cylindrical co-ordinates to sample the rest of the myocardium (Fig 7.2a)
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Maximum count circumferential profiles are automatically generated from the short- 
axis slices using a 2-part sampling scheme. First the apical cap is identified as 
stacked, short -axis slices that form a hemisphere . The apical cap is then sampled in a 
spherical co-ordinate system. The remaining portion of the myocardium, which is 
relatively cylindrical in shape is sampled slice by slice using a cylindrical co-ordinate 
system.
CEqual offers several polar maps for analysing the SPECT study. One polar map is 
called the "distance-weighted polar map” and is constructed so that every ring in the 
polar map is of the same width. This map offers an accurate assessment of the defect 
location. The “volume-weighted polar map” is constructed so that the volume of the 
apex and the remainder of the myocardium represented 011 the polar map is 
proportional to the volume of the corresponding slice. This volume weighted map 
makes the relative 2-dimensional area of the defect equal to the relative 3-dimensional 
volume of that defect. This quantitative technique offers analysis of the of the extent 
and severity of the stress perfusion defect (Fig 7.3).
The programme has been validated in populations with and without coronary artery 
disease with the following results (Kang et.al 1997):
Sensitivity: 90%
Normalcy rate: 83%
Localisation results:
LAD LCX RCA
Sensitivity 74% 70% 71%
Specificity 82% 88% 86%
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Since the CEqual programme used in this study was validated for Tc-99m sestamibi, 
the scans of patients recruited in the UK centre were reanalysed with the Liege 
programme which uses tracer specific databases for Tc-99m sestamibi and Tc-99m 
tetrofosmin images.
7.14h The Liege Quantitative Programme
This programme was developed and validated at the division of Nuclear Medicine, 
C.H.U. Sart Tilman, Liege, Belgium (Benoit et.al 1996). The system uses a 
360°elliptical sampling of radial slices to create activity profiles. After filtered 
backproj ection, images are oriented along the mid left ventricular axis to produce 
vertical, horizontal and 14 intermediary radial long axis slices a well as short axis 
slices (Fig 7.2b). The adequacy of the reorientation procedure is checked visually by a 
cine loop display of the radial slices rotating around the selected long axis. This 
method can be accurately applied even in patients with a large myocardial infarction. 
A composite long axis image is then created by summation of radial slices, and is 
used to manually trace the left ventricular wall outline and mask the non-cardiac 
activity, and also trace a non-cardiac region for determination of the reference 
background activity. Finally, the composite image is used to calculate a maximum 
count circumferential profile of the average cardiac activity. A two-dimensional polar 
map is then generated. Abnormal distribution is then identified by automatic 
comparison of the patient’s polar map with the threshold of a normal database defined
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on a pixel by pixel basis as the normal mean- 2.5 SD. The following parameters are 
calculated (Fig 7.4):
D efect severity = normal mean-patient value
normal mean-patient background value 
Maximum, mean and segmental severity values appear in the final display.
D efect extent: Each pixel of the polar map is calibrated to correct for the distortion 
resulting from the two-dimensional projection of 3-dimensional data. Defect extent is 
expressed both as a percentage of the left ventricular surface and in cm2' 
H ypoperfusion index : This is the product of the defect extent (as a percent of the left 
ventricular surface) and it’s mean severity. It represents the relative fractional mass of 
the hypoperfused myocardium and is an index of the size of the perfusion defect. The 
index is calculated for the whole left ventricle and also segment by segment.
This method differs from the Cequal programme in important ways. First, the use of 
radial rather than short axis slices allows evaluation of the left ventricular volume 
independent of the heart size and results in a more homogenous and sampling- 
independent partial volume effect. Secondly, the programme uses tracer specific 
databases for analysis of Tc-99m sestamibi and Tc-99m tetrofosmin scans. The 
programme has been validated in phantom and clinical studies (Benoit et.al 1996). 
There was 85% sensitivity and 78% specificity for overall coronary artery disease 
detection with reference to angiographic data.
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Cylindrical sampling 
Z
*  Y
Spherical sampling
F ig  7.2(a) Sam pling o f m yocardial slices in  CEq u al:
The apical cap is  identified as a hemisphere and sampled 
using spherical co-ordinates. The rest o f the m yocardium  
is sam pled using cy lin d rica l co-ordinates.
F ig  7.2 (b) R ad ia l sam pling co-ordinates used 
for the Lie ge  programme.
ftfc.U
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F ig  7 .3  R e p re se n ta tiv e  p o la r m ap  p ro d u ce d  
b y  the C E q u a l q u a n tita tive  p ro gram m e
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F ig  7.4 Q uantification o f defect extent and severity by the 
L ie ge  programme.
• Upper left quadrant: Polar map o f perfusion
• Upper right quadrant: Mean and m inim al segmental tracer 
uptake (%  m axim um )
• Low er left quadrant: M axim al and mean defect severity
• Low er right quadrant: Hypoperfusion index calculated using fixed 
(12% ) and measured backgrounds is shown. Each segment 
shows average severity (% ) o f hypoperfusion in white and the 
segmental fraction o f the global hypoperfusion index (%  x  10 ) in 
red. The total extent o f defect in %  and cm2 is also displayed.
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Sensitivity and normalcy rate were determined using standard formulae and compared 
using the McNemar’s test. The concordance between tetrofosmin and sestamibi for 
classifying scans (overall and segmental) into normal, reversible and fixed categories, 
and for overall image quality was determined using kappa statistics. Comparison of 
the two agents for diagnostic categorisation was performed using the Stuart-Maxwell 
test (Stuart 1995) of marginal homogeneity (paired comparison of the row totals with 
the column totals, to see whether the two agents classify the same proportion of 
patients into the three categories) and Bowker’s test for symmetry (Bowker 1948) (a 
comparison of the symmetry of individual cells about the table diagonal), and of 
image quality using the Wilcoxon signed rank test. All data are expressed as mean ± 
standard deviation (SD). A p value of <0.05 was considered significant.
7.15 S T A T IS T IC A L  A N A L Y S IS
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C H A P T E R  8 
R E S U L T S
8.1 Patient D em ography
Eighty eight patients were recruited into the study. Of these, 81 patients had 
angiographic coronary artery disease of 50% - 90% severity in one or epicardial 
coronary arteries. Seven subjects with < 5% probability of coronary artery disease 
volunteered to participate in the study, and were not subjected to coronary 
arteriography.
Fifty eight and 30 patients were recruited at the UK and Canadian sites, respectively. 
After randomisation, forty patients had the Tc-99m tetrofosmin scans performed first 
whereas the other 48 patients underwent Tc-99m sestamibi imaging first.
There were 63 males and 25 females in total, with a mean age of 59.7 ± 12 (range 34 
to 76) years and mean weight of 76.2 ± 15.4 Kg.
The subjects with low probability of coronary artery disease consisted of 4 males and 
3 females with a mean age of 37 ± 4.17 years.
8.2 Coronary Anatomy
Eighty one patients had 50-90% stenosis in one or two major epicardial coronary arteries; 45 
had single and 36 two-vessel disease. The 7 patients with <5% pre test probability of coronary 
artery disease were not subjected to coronary arteriography (fig. 8.1).
9 3
Of the 81 patients with coronary artery disease, 45 (55%) were smokers, 37 (45%) had 
hypertension, 12 (15%)had diabetes mellitus (all type II), 15 (19%) had
hypercholesterolaemia, and 25 (31%) had a history of premature coronary artery disease in a 
first degree relative. Fifty three patients had more than one risk factor (Fig 8.2).
Of the 7 subjects with <5% probability of coronary artery disease, none had risk factors.
8.3 Risk Factors
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Single  vessel disease Tw o-vessel disease
< 5 %  probability o f C A D
F ig  8.1 D is tr ib u t io n  o f  co ro n a ry  d ise a se  
in  the stu d y  p o p u la tio n  (n  =  8 8 )
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8.4 Haemodynamics during stress testing
The rest and peak heart rate and blood pressure during dipyridamole infusion are shown in 
Table 8.1. There were no significant differences in haemodynamic parameters during stress 
testing with Tc-99m sestamibi and Tc-99m tetrofosmin. The rate pressure product at peak 
stress for Tc-99m sestamibi and Tc-99m tetrofosmin were 11.4xl03 +19 and 11.3x 103 ±18, 
respectively, p=NS (Fig. 8.3).
8.5 Side effects of dipyridamole stress
The incidence of side effects was similar during Tc-99m sestamibi and Tc-99m tetrofosmin 
imaging, and was as follows:
Symptom Number o f patients
Tc-99m sestamibi Tc-99m tetrofosmin
chest pain 7 11
headache 20 23
dyspnoea 2 1
Flushing/light headedness 5 5
Palpitations 0 2
8.6 Aminophylline reversal
Sixteen and 18 patients were given aminophylline to reversible intolerable side effects from 
dipyridamole during Tc-99m sestamibi and Tc-99m tetrofosmin imaging, respectively
8.7 Detection of reversible perfusion defects
Tc-99m sestamibi demonstrated reversible defects in a significantly greater number of 
myocardial segments (363 and 285 reversible segments by Tc-99m sestamibi and Tc-99m 
tetrofosmin, respectively, pO.OOOl, Table 8.2, Fig 8.4). However, despite the fact that Tc- 
99m sestamibi demonstrated reversible perfusion defects in 50 patients compared to 45 by 
tetrofosmin, this difference did not achieve statistical signiflcance.(Table 8.3)
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8.8 Coronary anatomy of patients with discordant scans
Among patients with angiographic coronary disease, ten scans were positive by Tc-99m 
sestamibi (9 reversible, 1 fixed) and normal by Tc-99m tetrofosmin. In contrast, six scans 
were abnormal by Tc-99m tetrofosmin (5 reversible, 1 fixed) and normal by Tc-99m 
sestamibi; of these, only 4 patients had angiographic coronary disease, and 2 scans were false 
positive (p=NS, Table 8.4).
8.9 Ischaemic burden
The extent of perfusion abnormality demonstrated by Tc-99m sestamibi was also significantly 
greater compared to Tc-99m tetrofosmin (15.8 ± 12.3% and 12 ± 11.9%, respectively, p< 
0.01). In patients in whom both Tc-99m sestamibi and Tc-99m tetrofosmin studies showed 
reversible perfusion defects in identical segments, the defect/normal wall ratio was 0.60 ± 
0.15 for Tc-99m sestamibi and 0.73 ± 0.14 for Tc-99m tetrofosmin (p=0.01). In patients 
where reversible perfusion defects were not detected concordantly by both agents, the 
defect/normal wall ratio was 0.73 ±0.16 for Tc-99m sestamibi and 0.79 ±0.17 for Tc-99m 
tetrofosmin (p<0.01, Table 8.5, Fig 8.5-8.7).
After the initial blinded reading, the stress Tc-99m sestamibi and Tc-99m tetrofosmin scans 
of each individual patients were again read side-by -side with each other and assessed for the 
qualitative extent and severity of perfusion defects. By consensus it was agreed that:
• Tc-99m sestamibi and Tc-99m tetrofosmin scans showed equal comparable defect extent 
and severity in 43 cases
• Tc-99m sestamibi was superior in 32 cases
• Tc-99m tetrofosmin was superior in 13 cases
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8.10 Concordance for categorisation of defects
The overall concordance between Tc-99m sestamibi and Tc-99m tetrofosmin for categorising 
normal, fixed and reversible scans was only 78% (69/88, Kappa = 0.60, Table 8.3).
On a segmental basis, the concordance for similar categorisation was 86% (1291/1496, kappa 
= 0.67). Of 119 segments classified as normal by Tc-99m tetrofosmin, Tc-99m sestamibi 
demonstrated reversible and fixed defects in 101 and 18 segments, respectively. In contrast, 
there were only 54 segments classified as normal by Te-99m sestamibi where Tc-99m 
tetrofosmin detected abnormalities (49 reversible, 5 fixed; p<0.001 by both Stuart-Maxwell 
and Bowker’s tests, Table 8.2).
8.11 Detection of coronary artery disease
The overall sensitivity for the detection of mild to moderate coronary artery disease was not 
significantly different [63% (51/81) for Tc-99m sestamibi and 58%(47/81) for Tc-99m 
tetrofosmin, p=0.09 (Table 8.6)]. For both agents, sensitivity for detection of coronary artery 
disease was higher in patients with two- vessel disease (83% and 79% for Tc-99m sestamibi 
and Tc-99m tetrofosmin, respectively, p=NS) compared to those with single vessel disease 
(52% and 46% for Tc-99m sestamibi and Tc~99m tetrofosmin, respectively, p=NS).
8.12 Individual coronary territories
When individual coronary territories were considered, the sensitivity for the detection of left 
anterior descending coronary artery (LAD) disease for Tc-99m sestamibi and Tc-99m 
tetrofosmin respectively was 50 %(26/52) and 48% (25/52), left circumflex coronary artery 
(LCX) disease 50%(14/28) and 39%(ll/28) and right coronary artery(RCA) disease 
53%(16/30) and 37% (11/30), respectively (p = NS for all the above values, Fig 8.8).
The normalcy rate of Tc-99m sestamibi and Tc-99m tetrofosmin for the overall detection of 
coronary artery disease was 57%, detection of LAD disease 89%(32/36) and 81%(29/36), 
LC X  disease 87% and 87% (52/60), and RCA disease 78%( 45/58) and 76% (44/58), 
respectively, p=NS for all values.
9 9
8.13 Prediction of disease in more than one vessel
In the 29 patients with two- vessel disease, the ability of the two agents to demonstrate 
perfusion abnormalities in two vascular territories was examined. Tc-99m sestamibi correctly 
predicted the presence of two vessel disease in 14 patients, compared to 7 by Tc-99m 
tetrofosmin (Fig 8.9). This difference was statistically significant (p=0.02)
8.14 Image quality
There was overall agreement of 67% (59/88) for classification of images based on quality into 
excellent, good, fair and poor categories, p=NS. (Table 8.7). There was no significant 
difference in the overall quality of images produced by the two agents.
8.15 Subgroup analysis of patients recruited in the UK centre
The results of the subgroup analysis is shown in tables 8.8 and 8.9.
Using visual analysis, Tc-99m sestamibi detected a greater number of segments with 
reversible defects compared to Tc-99m tetrofosmin (125 for Tc-99m sestamibi compared to 
100 by Tc-99m sestamibi, p<0.001).
Using the Liege quantitative programme the Hypoperfusion index was significantly greater in 
the Tc-99m sestamibi (5.17 ± 6.5) compared to Tc-99m tetrofosmin scans (3.94 ± 5.1), 
p=0.003. Similarly, Tc-99m sestamibi also demonstrated defects of greater mean severity 
(23.51 ± 10.4 and 18.98 ±3.5, respectively p=0.006) and extent (% left ventricle involved 
16.34 ± 17.7 and 12.65 ± 14.3, respectively, p=0.003; left ventricular surface in cm2= 28.47 
±33.8 and 20.92 ± 25.1, receptively, p=0.0009) compared to Tc-99m tetrofosmin.
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MIBI TETRO p value
H eart rate (beats/min)
Rest 66 ±11 69 ± 12 ns
Maximal 80 ±15 81 ± 12 ns
Difference 14 ±14 12 ± 11 ns
B lo o d  p ressure  (mmHg)
Rest 148 ± 25 146 ± 25 ns
Maximal 143 ± 23 140 ± 24 ns
Difference -5 ± 17 -6 db 18 ns
MIBI = Tc-99m sestamibi TETRO = Tc-99m tetrofosmin
T a b le  8.1 H a e m o d y n a m ic  
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□  Tc-99m sestamibi ■  Tc-99m tetrofosmin
H R  =  heart rate (beats /min)
S B P =  systo lic blood pressure (m m H g) 
R R P =  rate pressure product (x  102)
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TETRO
MIBI
Normal Reversible Fixed
Normal 1011 49 5
Reversible 101 233 29
Fixed 18 3 47 !
1130 285 81
363
68
1065
(C e lls  =  m yocardial segments)
Segmental agreement: 1291/1496 (86.3%) kappa = 0.67 
MIBI was superior for detecting reversible defects (p<0.0001) 
MIBI = Tc-99m sestamibi 
TETRO = Tc-99m tetrofosmin
T a b le  8 .2  S e g m e n ta l a n a ly s is  o f  p e rfu s io n  d e fects
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□  Tc-99m sestamibi ■  Tc-99m tetrofosmin
F ig  8 .4  S e g m e n ta l d is tr ib u tio n  o f  p e rfu s io n  d e fe cts
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TETRO
Normal Reversible Fixed
Normal 28 5 1
Reversible 9 39 2
Fixed 1 1 2
38 45 5
(C e lls  =  patients)
Segm ental agreement: 69/88 (78.4% ) kappa=0.60, p=ns 
M IB I =  Tc-99m  sestam ibi 
T E T R O  =  Tc99m  tetrofosm in 
C A D  =  coronary artery disease
T a b le  8.3 D e m o n stra tio n  o f  p e rfu s io n  a b n o rm a litie s  
in  p a tie n ts w ith  m ild  to m oderate  C A D
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MIBI abnormal 
TETRO normal 
n= 10
MIBI normal 
TETRO abnormal 
n = 6
MIBI true positive =10 TETRO true positive = 4 
TETRO false positive = 2
1. LAD>70%, LCX>50% 1. LCX>70%
2. LAD>70% 2. LAD>70%
3. RCA>70% 3. LAD>50%
4. LAD>70%, RCA>70% 4. LAD>50%
5. RCA>50%
6. RCA>70%
7. LCX>50%
8. LAD>50% LCX>50%
9. RCA>70%
10. LCX>70%
MIBI = Tc-99m sestamibi
TETRO = Tc-99m tetrofosmin
LAD = Left anterior descending coronary artery
LCX = Left circumflex coronary artery
RCA = Right coronary artery
T a b le  8 .4  C o ro n a ry  a n a to m y in  p a tie n ts w ith  d isco rd a n t 
T c -9 9 m  se sta m ib i an d  T c -9 9 m  te tro fo sm in  re su lts
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MIBI TETRO p value
Reversible
segments
363 285 <0.0001
Defect extent 
( % L V  involved) 15.8+12.3% 12+11.9% <0.03
Defect severity 
(defect/normal w all 
count ratio)
0.60+0.15 0.73+0.14 0.01
MIBI = Tc-99m sestamibi TETRO= Tc-99m tetrofosmin
T a b le  8.5  Is c h a e m ic  b u rd e n  d e m o n strate d  b y  
T c -9 9 m  se sta m ib i an d  T c -9 9 m  te tro fo sm in
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p<0.01
segments with defect extent defect severity 
reversible (% LV defect/normal
defects involved) wall ratio)
□ Tc-99m  sestamibi ■  Tc-99m  tetrofosmin
F ig  8 .5  E s t im a t io n  o f  Is c h a e m ic  B u rd e n
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T E T R O
S  R
M IB I 
S  R
F ig  8.6 Representative horizontal and vertical long axes slices 
from the Tc-99m  tetrofosm in (T E T R O ) and Tc-99m  sestamibi 
(M IB I) stress(S) and rest (R ) S P E C T  im ages o f a 67 yeaj^old 
female patient w ith a 50%  stenosis o f her m id left anterior 
descending coronary artery and 90%  stenosis o f the proxim al left 
circum flex coronary artery. There are obvious infero-apical and 
lateral defects in the Tc-99m  sestam ibi scan w hile the Tc-99m  
tetrofosmin scan is only m ild ly  abnormal
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T E T R O
S  R
M IB I
S  R
F ig  8.7 Representative horizontal and vertical long 
axes, and short axis slices from Tc-99m  tetrofosm in 
(T E T R O ) and Tc-99m  sestam ibi (M IB I) stress (S ) and 
rest (R ) S P E C T  im ages o f a 64 year old man w ith 90%  
stenosis o f the proxim al left anterior descending 
coronary artery. The perfusion abnorm ality in vo lv in g  the 
apex, septum, anterior and w alls is more severe and 
extensive on the Tc-99m  sestam ibi scan
108b
MIBI TETRO p value
Overall 63 (51/81) 58(47/81) ns
Single vessel disease 51.9 (27/52) 46.2(24/52) ns
Two vessel disease 82.8 (24/29) 79.3(23/29) ns
MIBI=Tc-99m sestamibi 
TETRO= Tc-99m tetrofosmin
T a b le  8 .6  S e n s it iv ity  (% )  fo r  d e te ctio n  o f  
m ild  to m oderate  co ro n a ry  a rte ry  d ise a se
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60 n
50
40 -
%  30
20 -
10 -
LAD LCX 
(p=NS for all)
RCA
□  Tc-99m sestamibi ■Tc-99m tetrofosmin
L A D  =  left anterior descending artery 
L C X  =  left circum flex artery 
R C A  =  right coronary artery
F ig  8 .8  S e n s it iv ity  fo r d e te ctio n  o f  d ise a se  
in  in d iv id u a l co ro n a ry  te rrito rie s
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Tc-99m  Sestam ibi 
+ve -ve
Tc-99m
Tetrofosm in
+ve
-ve
6 1
00 14
14 15
p =  0.02 (M cN em ar’s test)
F ig .  8 .9  P re d ic tio n  o f  tw o -v e sse l d ise a se  (n = 2 9 )
i l l
TETRO
Poor Fair Good Excellent
Poor - - - 1
Fair - 1 - 1
Good - 3 16 10
Excellent - 1 13 42
0 5 29 54
Agreement: 59/88 (67%) Wilcoxon signed ranks test: p=ns
T a b le  8 .7  Im a g e  q u a lity
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MIBI
TETRO
Normal Reversible Fixed
Normal 841 25 4 870
Reversible 6 92 2 100
Fixed 3 8 5 16
850 125 11
(Cells = segments)
MIBI = Tc~99m sestamibi 
TETRO = Tc99m tetrofosmin
T a b le  8.8  S u b g ro u p  a n a ly s is  o f  p a tie n ts fro m  the U K  
centre: S e g m e n ta l a n a ly s is  o f  p e rfu s io n  d e fe cts.
M IB I  w a s su p e rio r fo r  d e te ctin g
re v e rs ib le  d e fe cts (p < 0 .0 0 1  b y  S tu a rt-M a x w e ll/ B o w k e r
te sts).
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Hypoperfusion*
Index
Mean defect 
severity
LV involvement 
(%) (cm)
MIBI 5.17±6.5 23.51±10.4 16.34 ±17.7 28.47±33.8
TETRO 3.94±5.1 18.98±3.5 12.65±14.3 20.92±25.1
p=0.006 p=0.006 p=0.003 p=0.0009
* Defect extent x severity (see text for details)
MIBI — Tc-99m sestamibi TETRO = Tc-99m tetrofosmin
T a b le  8 .9  S u b g ro u p  a n a ly s is  u s in g  the L ie g e  
q u a n tific a tio n  p ro gra m m e .
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C H A P T E R  9 
D IS C U S S IO N
This prospective study compared the diagnostic sensitivity of two commonly used 
radionuclide perfusion tracers Tc-99m sestamibi and Tc-99m tetrofosmin for the 
detection of coronary artery disease and reversible perfusion defects. The study was 
based on the results of previous animal work that demonstrated a lower myocardial 
extraction fraction of Tc-99m tetrofosmin compared to Tc-99m sestamibi, leading to 
concerns that the consequent reduction in defect contrast could lead to 
underestimation of perfusion defects by Tc-99m tetrofosmin. In contrast to previous 
studies comparing these two agents, the patients population and imaging protocol in 
this study were carefully chosen to provide optimum conditions for the effects of a 
low myocardial extraction fraction to manifest. Hence, only patients with mild to 
moderate coronary artery disease and no previous myocardial infarction (where defect 
contrast is already low) were included, and high dose dipyridamole stress was used to 
induce maximum coronary vasodilatation.
9.1 DETECTION OF CORONARY ARTERY DISEASE.
The findings of the current study indicate that the diagnostic sensitivity of Tc-99m 
sestamibi and Tc-99m tetrofosmin for the detection of coronary artery disease using 
dipyridamole SPECT imaging in this population of patients with mild to moderate 
disease is similar. In the 81 patients with angiographic coronary disease, the overall 
sensitivity was 63% (51/81) and 58% (47/81) for Tc-99m sestamibi and Tc-99m 
tetrofosmin, respectively (p= NS). These values are lower than previously reported 
sensitivity values for both agents, and this was expected for reasons discussed below.
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Several studies have previously assessed the diagnostic accuracy of Tc-99m sestamibi 
SPECT imaging for the detection of coronary artery disease (Iskandrian et.al 1989b; 
Kahn et.al 1989; Kiat et.al 1989; Maddahi et.al 1990; Miller et.al 1997).
Kahn and colleagues (1989) compared Tc-99m sestamibi and thallium-201 in 38 
patients with coronary artery disease and 12 normal subjects using a quantitative 
SPECT technique. The sensitivity for detection of coronary artery disease was 84% 
(32/38) and 94% (34/38) for thallium-201 and Tc-99m sestamibi, respectively 
(p=NS). Sixty and 79% of individual coronary arteries with stenosis>50% were 
detected by thallium-201 and Tc-99m sestamibi, respectively (p<0.05). Image quality 
was superior with Tc-99m sestamibi. In this study, interestingly and contrary to the 
results of most other studies, Tc-99m sestamibi also detected a significantly greater 
number of segments with reversible perfusion defects.
Iskandrian et al (1989b) found similar diagnostic sensitivity for Tc-99m sestamibi and 
thallium-201 in 28 patients with coronary arteiy disease (84% and 82%, respectively), 
and better quality images with Tc-99m sestamibi. In 11 patients without significant 
coronary artery disease, they demonstrated a slightly, but not significantly higher 
specificity of Tc-99m sestamibi compared to thallium-201 (100% vs. 82%, 
respectively). Similarly, Kiat et al (1989) demonstrated sensitivities of 93% and 80% 
(p=NS) for Tc-99m sestamibi and thallium-201, respectively, in 36 patients. Overall 
specificity was 75% for both tracers. This study also showed a higher sensitivity for 
SPECT compared to planar imaging.
It must be noted that in all the above studies, the numbers of patients studied were 
relatively small.
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The phase III multicentre study (Maddahi et.al 1992) included 294 patients, and the 
overall sensitivities were 92% and 90% for Tc-99m sestamibi and thallium-201, 
respectively. As was seen in our study, coronary artery disease detection improved 
with increasing extent of disease, with higher sensitivity for multivessel compared to 
single vessel disease for both Tc-99m sestamibi and thallium-201. Normalcy rates 
were 92% and 94%, respectively, for Tc-99m sestamibi and thallium-201.
A pooled analysis of 81 patients collated by Maddahi et al (1990) yielded 90% 
sensitivity and 93% specificity for the detection of coronary artery disease by Tc-99m 
sestamibi imaging.
Tc-99m tetrofosmin was introduced into clinical practice after Tc-99m sestamibi and 
there is relatively less data on its diagnostic accuracy. In the phase III multicentre trial 
(Zaret et.al 1995) in which 10 European and American centres participated, 252 
patients were included. In the 181 patients with angiographically proven coronary 
artery disease, the sensitivity of Tc-99m tetrofosmin and thallium-201 were 77% and 
83%, respectively, and not significantly different. Again, sensitivity was related to the 
extent of coronary disease, with sensitivities of 74%, 80% and 90% noted for one, two 
and three- vessel disease, respectively. Although specificity was low for both agents, 
which is probably a reflection of post- test referral bias for coronary arteriography, the 
normalcy rate was 97% with both agents. Other smaller studies have shown similar 
results (Tamaki et.al 1994)
Several studies have also reported diagnostic accuracy for the detection of coronary 
artery disease with dipyridamole Tc-99m sestamibi. Miller et al (1997) reported a 
sensitivity of 91% in 244 patients unable to exercise. Parodi et al (1991), Kettunen et
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al (1991) and Sciagra et al (1994) used high dose dipyridamole stress and reported 
sensitivities of 81%, 95% and 100% respectively.
There have been relatively fewer studies reporting on the sensitivity of dipyridamole 
stress in conjunction with Tc-99m tetrofosmin imaging. In a three-centre American 
study, He et al (1997) reported sensitivity and specificity of 85% and 55% 
respectively, in 64 patients. In another study, Fulcuzawa (1996) demonstrated 
sensitivity and normalcy rate of 83% and 100%, respectively.
The relatively low sensitivity values of 63% for Tc-99m sestamibi and 58% for Tc- 
99m tetrofosmin obtained in the current study were expected because of the deliberate 
selection of patients with only mild to moderate coronary artery disease (50%-90% 
stenosis in one or two epicardial vessels) and the exclusion of patients with previous 
myocardial infarction and more severe coronary disease (three vessel disease, >90% 
stenosis in any arteiy and left main stem disease). The previous studies alluded to 
above included a more heterogeneous population including patients with severe 
coronary disease and previous myocardial infarction. Both these factors would result 
in an increased sensitivity of myocardial perfusion imaging for the detection of 
coronary artery disease.
It is also possible that some of the patients in our study reported to have mild stenosis 
(50%-70%) by qualitative coronary arteriography and normal perfusion scans by both 
agents may in fact, have had non-flow limiting stenosis. The presence of a large inter­
observer variability in estimation of stenosis severity by visual analysis of coronary 
arteriograms is well established (DeRouen et.al 1977; Marcus et.al 1988a; White et.al
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1984). In one study, four experienced interpreters agreed on the significance of a 
stenosis in the left anterior descending coronary artery in only 45% of arteriograms 
(Zir et.al 1976). This raises the issue of the appropriateness of using coronary 
arteriography as the “gold standard “against which the diagnostic sensitivity of other 
imaging modalities is referenced. Especially in the case of mild to moderate coronary 
stenosis, functional imaging techniques like myocardial perfusion imaging and stress 
echocardiography may be superior to coronary arteriography for identifying 
physiologically significant stenosis
As seen with the previous studies, the sensitivity for detection of single vessel disease 
was lower than the sensitivity for the detection of two-vessel disease. It was 51% and 
42% for Tc-99m sestamibi and Tc-99m tetrofosmin, respectively, for the detection of 
single vessel disease, compared to 83% and 79%, respectively, for the detection of 
two vessel disease.
When individual coronary territories were considered, the sensitivity for the detection 
of left anterior descending coronary artery (LAD) disease for Tc-99m sestamibi and 
Tc-99m tetrofosmin respectively was 45% (26/57) and 44% (25/57), left circumflex 
coronary artery (LCX) disease 31%(9/21) and 40%(11/21) and right coronary artery 
(RCA) disease 45% (14/31) and 32% (46/31), respectively (p = NS for all the above 
values).
The normalcy rate of Tc-99m sestamibi and Tc-99m tetrofosmin in the low 
probability group was 57%. However the small number of patients with low 
probability of coronary artery disease were included primarily to eliminate any
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reporting bias that might have arisen if all patients were expected to have coronary 
disease, and normalcy data obtained from such small numbers may not be a true 
reflection of the actual specificity of these agents.
Previous studies that reported on the sensitivity of Tc-99m sestamibi or Tc~99m 
tetrofosmin for diagnosing disease in individual coronary artery territories did not 
demonstrate any significant differences in sensitivity for detection of disease in the 
three vascular territories (Kettunen et.al 1991; Tartagni et.al 1991; Zaret et.al 1995).
9.2 ESTIMATION OF ISCHAEMIC BURDEN.
The most important finding of the current study was the demonstration of a greater 
ischaemic burden by Tc-99m sestamibi compared to Tc-99m tetrofosmin.
Tc-99m sestamibi detected a greater number of segments with reversible perfusion 
defects (363 and 285 segments, respectively, p<0.0001) and also demonstrated a 
greater extent of perfusion defect, calculated using the CEqual quantitative 
programme as the percentage of left ventricular myocardium involved by the stress 
defect (15±12.3% and 12 ± 11.4% for Tc-99m sestamibi and Tc-99m tetrofosmin, 
respectively, p<0.001). Similarly, when defect severity was calculated as the ratio of 
counts between the defect and a normal wall, Tc-99m sestamibi defects were 
significantly more severe (0.60 ± 0.15 Vs 0.73 ± 0.14, respectively, p=0.01, for 
patients with reversible defects detected by both agents, and 0.73 ± 0.16 Vs 0.79 ± 
0.17, respectively, p<0.01 for defects seen by either agent alone).
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This suggests that Tc-99m tetrofosmin may underestimate defect severity in patients 
with mild to moderate coronary artery disease, a finding that may have profound 
implications for clinical myocardial perfusion imaging.
One of the principal applications of non-invasive cardiology techniques is to identify 
patients at high risk for future cardiac events. Myocardial perfusion imaging has 
several advantages over exercise electrocardiography for risk stratification. Firstly, 
sensitivity for detection of ischaemia by scintigraphic criteria may be increased by as 
much as 30% to 35% as compared with exercise ST segment depression alone (Beller 
1994; Brown 1991). This enhanced sensitivity is more evident in patients who fail to 
achieve at least 85% of maximum predicted heart rate for age during exercise 
(Esquivel et.al 1989), a group that constitutes as much as 15%-20% of patients 
referred for stress testing. Second, myocardial perfusion imaging is able to accurately 
localise ischaemia, and thereby identify patients with high risk disease patterns like 
proximal left anterior descending coronary artery and left main stem disease. Thirdly, 
multivessel disease patterns can be identified. Several studies have shown that a 
worse prognosis for perfusion defects in multiple vascular territories compared to a 
single vessel territory (Iskandrian et.al 1985; Ladenheim et.al 1986),(Travin et.al 
1993), (Melin et.al 1990). Some of these studies (Brown et.al 1989; Kaul et.al 1988b; 
Melin et.al 1990) have shown that perfusion imaging variables are superior to cardiac 
catheterization variables for assessing risk in patients with chronic coronary artery 
disease.
These concepts have been validated in several studies. The most consistent 
observation in the literature concerning the prognostic value of myocardial perfusion 
imaging is that the presence and extent of reversible perfusion defects predicts future
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cardiac adverse events (Brown 1999). A direct relationship between the presence and 
extent of jeopardised viable myocardium, as indicated by reversible perfusion defects 
on thallium-201 scintigraphy, was first demonstrated in 1983 by Brown (1983) and 
later confirmed in larger studies by other workers (Kaul et.al 1988a; Ladenheim et.al 
1986). These studies showed that the presence, extent and number of reversible 
thallium-201 defects is the most accurate predictor of future cardiac events (Brown 
1991), (Brown 1999) and established an important principle: Although the presence of 
jeopardised viable myocardium identifies patients at increased risk for cardiac events, 
more importantly cardiac risk is directly related to the extent of jeopardised 
myocardium.
They also established the superiority of scintigraphic variables over exercise 
electrocardiography and cardiac catheterisation for risk stratification in coronary 
disease (Gill et.al 1987; Kaul etal 1988a; Kaul et.al 1988b).
Similar data are now available using Tc-99m sestamibi imaging in conjunction with 
either exercise testing or dipyridamole stress (Berman et.al 1995; Heller et.al 1995; 
Miller et.al 1994b; Stratmann et.al 1994). In 548 patients with stable angina, who 
underwent exercise Tc-99m sestamibi imaging, Stratmann and colleagues (1994) 
reported a cardiac event (non-fatal myocardial infarction or death) rate of 0.5%, 8% 
and 11% in patients with a normal scan, reversible perfusion defects in one vascular 
territory and reversible defects in multiple vascular territories. These investigators 
have reported similar observations using dipyridamole stress Tc-99m sestamibi 
perfusion imaging (Miller et.al 1994b). Heller et al (1995) have shown that in 512 
patients with stable angina, that the cardiac event rate was directly related not only to
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the presence of reversible perfusion defects on dipyridamole Tc-99m sestamibi 
imaging (12.3% and 1.7% in patients with and without reversible perfusion defects, 
respectively), but also to the extent of perfusion abnormality.
Another facet of risk stratification using myocardial perfusion imaging is the 
prognostic value of a normal scan. Many studies including some using dipyridamole 
Tc-99m sestamibi imaging, have shown that patients with a normal myocardial 
perfusion scan have a low cardiac adverse event rate (<1% per year) (Brown et.al 
1994; Hachamovitch et.al 1996; Heller et.al 1995; Raiker et.al 1994; Soman et.al 
1999; Stratmann et.al 1994). This important finding suggests that patients who are 
referred with suspected or known coronary artery disease and have normal perfusion 
scintigraphy do not require further investigation. This applies equally to patients with 
abnormal coronary arteriography, or exercise electrocardiography (Abdel-Fattah A. 
et.al 1994; Brown et.al 1993; Fagan et.al 1992; Kaul etal 1988a; Schalet et.al 1993).
These results from previous studies underscore the importance of the results of the 
current study. Quite obviously, the underestimation of the extent and severity of 
reversible perfusion defects would impact significantly on the prognostic value of a 
perfusion tracer. In addition, it must be noted that there are no large outcome studies 
where the prognostic value of Tc-99m tetrofosmin has been evaluated. In the light of 
the current results, it would be prudent to say that the prognostic data relating to Tc- 
99m sestamibi imaging should not be empirically extrapolated to Tc-99m tetrofosmin 
imaging when vasodilator stress is used. Currently there is no data to suggest that
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similar differences between the two agents occur during exercise or inotropic stress 
testing
9.3 MECHANISMS
The myocardial uptake of an ideal perfusion tracer would parallel myocardial blood 
flow across the entire range obtainable in humans. However, unlike microspheres, the 
myocardial uptake of all the currently available radionuclide tracers is limited by a 
“roll-off’ phenomenon whereby the myocardial uptake of the tracer does not increase 
beyond a point despite further increases in myocardial blood flow. Therefore, the 
amount of tracer taken up by the myocardium is proportional to flow only within a 
finite range of blood flow, and changes to a plateau at high flow rates when the 
extraction becomes limited by membrane transport. At high flow rates, less tracer is 
directly extracted during the capillary transit, and the tracer that diffuses back into the 
capillary channel is less likely to be reabsorbed before it reaches the venous bed. The 
lower the first-pass extraction fraction of a tracer, the less the tracer is extracted at 
hyperaemic flows. This phenomenon reduces perfusion defect contrast as a result of 
reduced myocardial uptake of tracer in the normally perfused areas, and could affect 
perfusion defect size, severity and the detection rate of reversible defects.
The relationship between myocardial blood flow and uptake of radionuclide perfusion 
tracers has been studied extensively in animal research.
In a study of 8 closed -chested swine with left anterior descending coronary artery 
stenosis of 80%, Gray and Gewirtz (1991) showed that Tc-99m teboroxime with its
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high myocardial extraction fraction (Emax 0.72 ± 0.09) paralleled myocardial blood 
flow up to rates of 5 ml/g/min. Unfortunately, the rapid clearance of this agent from 
the myocardium has made it difficult to use this agent clinically (Heller 1996). 
Similarly, thallium-201 (Emax 0.59 to 0.73) parallels blood flow rates of at least 3 
ml/g/min, beyond which there is a plateau effect, with no further increases in 
thallium-201 uptake despite further increases in myocardial blood flow (Nielsen et.al 
1980a) . Therefore both thallium-201 and Tc-99m teboroxime exhibit a plateauing 
effect, but this is generally above the blood flow range encountered during 
conventional exercise or pharmacological stress testing.
However the extraction fraction of Tc-99m sestamibi (E max 0.31 to 0.73) is lower 
than that of thallium-201 and that of Tc-99m tetrofosmin even lower (Emax
0.24+0.09). In an anaesthetised canine model with varying degrees of left circumflex 
artery stenosis in which myocardial blood flow was increased to levels up to 5 
ml/g/min with dipyridamole infusion, Glover et al (1990b) showed that the 
relationship between Tc-99m sestamibi uptake and blood flow levels was linear up to 
flows of 2 ml/g/min. Other studies suggest that Tc-99m tetrofosmin, with its lower 
myocardial extraction fraction, plateaus when blood flow increases 1.5 fold (Glover 
et.al 1997; Heller 1996; Sinusas et.al 1994)
The effect of a low myocardial extraction fraction on detection of perfusion defects 
has been demonstrated in several animal and clinical studies.
In an elegant study comparing thallium-201 and Tc-99m sestamibi imaging by Glover 
et al (1995), 22 dogs were studied with flow transducers on the left anterior 
descending and circumflex coronary arteries. In 6 dogs with no coronary stenosis, 
adenosine was infused directly into the left anterior descending coronary artery,
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whereas 16 dogs with either critical (n=7) or mild (n=9) stenosis of the left anterior 
descending coronary artery received an intravenous infusion. At peak flow thallium- 
201 and Tc-99m sestamibi were injected. In the 6 non-stenotic dogs, a five-fold 
increase in coronary flow increased thallium-201 and Tc-99m sestamibi uptake by 
only 202±6% and 138±4%, respectively. In dogs with a critical stenosis, the ratio of 
flow in the abnormal to normal beds was 0.17+0.03. As determined by defect to 
normal wall count ratios, this flow disparity was underestimated by Tc-99m sestamibi 
(0.53 ± 0.06) compared to thallium-201 (0.37 ± 0.5), p<0.05. Similarly, in dogs with a 
mild stenosis, the flow ratio (0.43+0.04) was again underestimated by Tc-99m 
sestamibi (0.79+0.03) compared to thallium-201 (0.62+0.04) p<0.02.
In another similar study by the same group (Glover et.al 1997), Tc-99m tetrofosmin 
(0.67+0.05 and 0.81+0.04, for critical and mild stenosis, respectively) underestimated 
the stenotic to normal flow ratios (0.22+0.02 and 0.44+0.05 in the critical and mild 
stenosis groups, respectively) compared to thallium-201 (0.37+0.04 and 0.58+0.04, 
for critical and mild stenosis, respectively). This study also reported a lower first pass 
myocardial extraction fraction for Tc-99m tetrofosmin (54%±3.7%) compared to Tc- 
99m sestamibi (68.3% ± 4.7%).
These data suggest that thallium-201, by virtue of its greater myocardial extraction 
fraction, more closely approximates the flow disparity between normal and stenotic 
coronary vascular beds. Although, there are no studies directly comparing Tc-99m 
sestamibi and Tc-99m tetrofosmin in similar animal models, it would be logical to 
extrapolate that the greater defect extent, severity and reversibility seen with Tc-99m 
sestamibi in the current study may be explained by its relatively higher myocardial 
extraction fraction compared to Tc-99m tetrofosmin.
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Several clinical studies have compared the detection of perfusion defects by thallium- 
201 and one of the technetium agents in patients with known coronary artery disease. 
Maublant and colleagues (1992) compared defect size on rest SPECT imaging in 15 
patients with previous myocardial infarction and exercise SPECT imaging in 15 
patients with documented coronary artery disease. In patients with coronary artery 
disease, the mean size of defect on the exercise scans, measured quantitatively as the 
percentage of the left ventricular volume involved, was significantly larger with 
thallium-201 (6.7±5.2%) compared to Tc-99m sestamibi (4.6±5.2%, p<0.05). There 
was no difference in the defect size in patients with myocardial infarction studied only 
at rest.
In a similar study in 24 patients, Narahara et al (1990) showed that exercise SPECT 
defects (expressed as left ventricular mass) were larger on thallium-201 imaging 
(52±46.2 g) compared to Tc-99m sestamibi (42±39.9g, p<0.05). Again, redistribution 
thallium-201 and resting Tc-99m sestamibi images sizes were not significantly 
different (32 ± 34.7 Ys 33±38.4 g).
Tamaki and colleagues (1994) compared Tc-99m tetrofosmin imaging to thallium-201 
imaging in 25 patients who also had coronary arteriography. The two agents had 
similar sensitivity and specificity for the detection of coronary artery disease. There 
was no significant difference in number of reversible segments detected by each 
agent. However, it must be noted that these authors used a stress-3-hour redistribution 
protocol for thallium-201 in this study, and therefore, both thallium-201 and Tc-99m 
sestamibi imaging may have underestimated true defect reversibility. To assess 
differences in the severity of perfusion abnormalities, the authors compared the
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perfusion score in hypoperfused segments and the tracer distribution using a bull’s 
eye polar map. The average perfusion defect score in the stress tetrofosmin images 
was greater than in the stress thallium-201 images (2.3±1.01 and 2.23 ±1.05, 
respectively, p=0.007) indicating lower defect contrast in the former. When only 
segments showing redistribution on stress thallium-201 imaging were analysed the 
difference in the stress perfusion defect scores was more striking (1.58± 0.91 Vs 
1.17±0.62; p=0.004). Similarly, the defect to normal wall count ratio in hypoperfused 
segments was higher on the stress Tc-99m tetrofosmin (63.35±13.5%) compared to 
stress thallium-201 (60.4%±12.2; p=0.0006) images. Again, when segments showing 
redistribution on the stress thallium-201 images were analysed, the difference was 
greater (63.9%±11.55 Vs 59.8%±8.7%; p=0.004). In this study, the resting 
distribution of tetrofosmin in hypoperfused segments was also slightly higher 
(67.6%±14%) than that of delayed thallium-201 (65%±12.5%; p=0.002)
Matsunari and colleagues (1996) compared exercise-rest Tc-99m tetrofosmin and 
exercise-reinjection thallium-201 imaging in 20 patients with single-vessel coronary 
artery disease and showed a smaller defect on the stress Tc-99m tetrofosmin study 
(6.9±3.9 segments vs. 8.8±3 segments, p<0.01), with similar defect sizes on the rest 
Tc-99m tetrofosmin and redistribution thallium-201 study. The mean defect sizes 
during exercise as determined by quantitative analysis was similarly smaller on the 
Tc-99m tetrofosmin scans. Also, 58 perfusion zones with initial thallium-201 defects 
had corresponding normal Tc-99 tetrofosmin uptake.
Shanoudy et al (1998) performed dipyridamole Tc~99m tetrofosmin and thallium-201 
SPECT imaging in 26 patients with angiographic coronary artery disease. Thallium-
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201 identified more reversible and partially reversible defects than Tc-99m 
tetrofosmin (89 vs. 55, p=0.002). The average defect magnitude (percent normal) was 
significantly greater with thallium-201 imaging compared to Tc-99m tetrofosmin 
imaging for both defects graded as completely reversible (58 ± 3% vs. 49 ± 3%) and 
partially reversible (45 ± 5% vs.30 ± 55). The number and magnitude of fixed defects 
was similar with both agents. An interesting finding of this study was that thallium -  
201 studies revealed defects in 13 (68%) of the 19 coronary supply territories 
perfused by vessels with 50% to 70% stenosis (10 reversible), where as Tc-99m 
tetrofosmin identified 7 defects (3 reversible) in the same 19 territories (p=0.05). Both 
agents identified an equal number of defects in territories supplied by 71% to 99% 
stenosis or total occlusion (76% and 72%, respectively).
Nakajima et al (1993) reported a lower detection rate of exercise -induced ischaemia 
associated with infarction with Tc-99m tetrofosmin compared to thallium-201.
The results of the above studies can be summarised as follows:
1. Both Tc-99m sestamibi and Tc-99m tetrofosmin underestimate myocardial flow 
heterogeneity compared to thallium-201 and therefore, result in stress perfusion 
defects of smaller extent, severity and reversibility compared to thallium-201. 
Tc-99m tetrofosmin has a lower myocardial extraction fraction than Tc-99m 
sestamibi
2. The extent of resting defects on the Tc-99m scans is similar to the redistribution 
or reinjection scan defect extent on the thallium-201 scans. This finding suggests 
the “roll-off’ phenomenon limiting myocardial tracer uptake and resulting in 
smaller perfusion defects occurs at the higher myocardial flow rates, while tracer 
extraction may be more similar at the lower flow rates. This finding has several
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implications: Firstly, it means that fixed defects in areas of previous myocardial 
infarction would be detected equally by perfusion tracers with different 
myocardial extraction fractions. This has been borne out by a previous study by 
Leon et al (1992) in dogs which showed that partial coronary occlusions 
produced smaller Tc-99m sestamibi defects than did thallium-201, where as this 
difference was not observed with near total coronary occlusions. It also means 
that the roll off phenomenon is more likely to affect vasodilator as opposed to 
exercise stress, since the latter induces relatively smaller increases in myocardial 
blood flow (Heller 1996). Cuocolo et al (1996) reported a lesser Tc-99m 
tetrofosmin defect magnitude on adenosine stress images compared with exercise 
images when exercise and vasodilator stress studies were performed in the same 
group of patients. Therefore, clinical studies with a high proportion of patients 
with severe coronaiy artery disease and previous myocardial infarction, and those 
that employ dynamic exercise for stress testing are likely to demonstrate similar 
defect sizes on imaging with agents with different myocardial extraction 
fractions. Finally, this finding supports the conclusion that the observed 
differences in the extent and severity of defects produced by thallium-201 and 
Tc-99m labelled agents are unlikely to be due solely to technical differences 
including the better resolution provided by the Tc-99m- labelled tracers.
1 3 1
9.4 PREVIOUS COMPARATIVE STUDIES OF Tc-99m SESTAMIBI AND 
Tc-99m TETROFOSMIN.
Only two studies have previously made intra-individual comparisons of Tc-99m 
sestamibi with Tc-99m tetrofosmin.
Flamen et al (1995) studied 30 patients who underwent single day rest and 
dipyridamole stress SPECT imaging with both Tc-99m sestamibi and Tc-99m 
tetrofosmin. Heart to liver count ratios were significantly higher with Tc-99m 
tetrofosmin compared to Tc-99m sestamibi for both the resting (1.19±0.39 Vs 
0.96±0.45;p<0.05) and stress studies (1.37±0.37 vs. 1.05±0.42; p<0.05). Heart-lung 
ratios were similar for both agents. There was no significant difference in the 
diagnostic accuracy, detection of reversible perfusion defects and the extent or 
severity of defects detected by the two agents. In addition they demonstrated no 
significant differences in the perfusion indices of the eight inferior and infero-septal 
myocardial segments and concluded that the more favourable heart lung ratio with 
Tc-99m tetrofosmin was too modest to influence image quality. However, the results 
of coronary arteriography were not reported by this group.
A study by Acampa and colleagues (1998) included 32 patients, of whom 25 had 
coronary artery disease, and showed no significant differences between Tc-99m 
sestamibi and Tc-99m tetrofosmin in diagnostic accuracy, defect extent, severity or 
reversibility. Fifteen of these patients had previous myocardial infarction, 14 had 
multi-vessel disease and the mode of stress chosen was bicycle exercise.
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There are several important differences between these studies and onr study which 
may have had a bearing on the results.
Ours was a prospective study with a carefully chosen patient population.
As discussed above, studies that include a large proportion of patients with previous 
myocardial infarction and severe coronary artery disease are unlikely to show 
differences between perfusion tracers occurring as a result of dissimilar myocardial 
extraction fractions. Hence the current study included only patients with mild to 
moderate coronary artery disease and deliberately excluded patients with severe 
disease or previous myocardial infarction. In the study by Flamen et al , patients did 
not have coronary arteriography performed, and therefore, the severity of coronary 
disease remains a matter of speculation. Acampa et al included a significant 
proportion of patients with severe disease and previous myocardial infarction. 
Although patients underwent coronary arteriography in this study, the temporal 
relationship between coronary arteriography and perfusion imaging was not 
described. In our study coronary arteriography was performed before perfusion 
imaging and therefore, the decision to perform the former was never influenced by the 
later, thus eliminating the possibility of any referral bias.
W e  specifically chose vasodilator stress in preference to dynamic exercise to produce 
the maximum increase in myocardial blood flow. It is well known that while exercise 
produces 2 to 3-fold increase in myocardial blood flow (Leppo 1996), vasodilator 
stress increases myocardial blood flow 3 to 5-fold (Iskandrian et.al 1994; McLaughlin 
et.al 1994; Nussbacher et.al 1995). The high dose (0.84 mg/kg) dipyridamole protocol 
used in this study has been shown to produce maximal vasodilatation and have better
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sensitivity for the detection of reversible profusion defects compared to the standard 
dose (Lalonde et.al 1994). As discussed in the previous section, the lower increases in 
myocardial blood flow induced by exercise stress may preclude the manifestations of 
the effects of a low myocardial extraction fraction.
Finally, our study was considerably larger and included 88 patients, compared to 25 
by Flamen et al and 32 by Acampa et al.
The fact that we were able to demonstrate a difference between Tc-99m sestamibi and 
Tc~99m tetrofosmin is most likely related to the above differences in sample size, 
patient selection and the modality of stress testing used.
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The use of CEqual software may not be optimal since it is not validated for Tc-99m 
tetrofosmin. However we were limited by the lack of a quantification programme 
validated for both agents. Although the CEqual software to quantify perfusion defects 
has thus far been validated for Tc-99m sestamibi, but not for Tc-99m tetrofosmin, it 
compares the relative distribution of tracer in the myocardium to normal limits. Since 
the distribution within the myocardium should not be different for the two agents, the 
use of this software to compare results within a single patient should be valid 
(Wackers 1996). Furthermore, at least two previous studies have suggested that the 
choice of the quantitative programme is unlikely to influence the imaging results to 
any significant degree (Wackers 1996; Widding et.al 1997). Also, subgroup analysis 
of patients recruited by the U K  centre using the Liege quantitative programme 
showed similar differences between Tc-99m sestamibi and Tc-99m tetrofosmin.
The presence of significant inter-observer variability in the reporting of qualitative 
coronary arteriography is well established (Zir et.al 1976). (DeRouen et.al 1977; 
Marcus et.al 1988a; White et.al 1984) It is possible that some of the milder stenosis in 
our patients may in fact, have been non-flow limiting, thus explaining the significant 
number of normal scans and the seemingly low sensitivity of SPECT imaging in this 
population.
The small number of patients with low probability of coronary artery disease were 
included to eliminate any reporting bias that might arise if all patients were expected 
to have coronary artery disease. Hence normalcy values calculated from this study 
may not be accurate.
9.5 S T U D Y  L I M I T A T I O N S
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Although there was no difference in the diagnostic accuracy of the two agents for the 
detection of coronary artery disease, there was a trend in favour of Tc-99m sestamibi. 
This could a reflection of an inadequate sample size. Larger comparative studies are 
required to determine if there is a true difference in diagnostic sensitivity.
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9.6 C O N C L U S I O N S  A N D  C L I N I C A L  I M P L I C A T I O N S
This study compared two Tc-99m-labelled flow tracers, Tc-99m sestamibi and Tc- 
99m tetrofosmin, that are commonly used for myocardial perfusion imaging and 
showed that in a patient population with predominantly mild to moderate, single­
vessel coronary artery disease, Tc-99m sestamibi demonstrates greater perfusion 
defect extent, severity and reversibility. Compared to Tc-99m tetrofosmin, it also 
more often correctly identifies patients with disease in more than one coronary artery. 
Although there was no significant difference in the diagnostic sensitivity of the two 
agents for the detection of coronary disease, there was a trend in favour of Tc-99m 
sestamibi. Larger comparative studies are required to determine if this trend is a 
reflection of a true difference in the ability of these two agents to detect mild to 
moderate coronary disease. The quality of images produced by the two agents was 
comparable.
Such differences in the ability of two commonly used radionuclide tracers to detect 
reversible perfusion defects and determine the extent and severity of coronary artery 
disease could have significant diagnostic and prognostic implications. Myocardial 
perfusion imaging is now routinely used for diagnosis and risk stratification in 
coronary disease. A  recent survey of the practice of Nuclear Cardiology in the United 
Kingdom (Pennell et.al 1998) revealed that 125 (65%) of the 192 responding nuclear 
medicine centres performed myocardial perfusion imaging. An estimated total of 
31,300 patients underwent myocardial perfusion imaging in 1994 (62% in regional 
centres). Thallium-201 was at that time the most preferred agent (used in 63% of 
scans). Tc-99m sestamibi was used in approximately one-third of studies, and more
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commonly used in district general hospitals. Tc-99m tetrofosmin was not yet licensed 
at the time of this survey but was included in a small percentage of survey returns 
because of its use in clinical trials. Almost half the studies were performed with 
pharmaceutical stress. A  striking finding was the reported increase of 350% in the 
number of myocardial perfusion scans performed between 1988 and 1994. Coupled 
with a projected annual increase in nuclear cardiology activity of approximately 23%, 
these figures provide some indication of the rapid growth of this speciality that has 
already occurred in the recent years, with further expansion being anticipated. With 
the distinct advantages offered by Tc-99m for gamma camera imaging, these Tc-99m 
labelled agents are likely to supersede thallium-201 as the perfusion tracer of choice. 
Preliminary results from a more recent survey conducted by the same group 
(Prvulovich E, personal communication) estimated the number of patients who 
underwent myocardial perfusion imaging in 1997 at 49,275. There has been a 
significant shift in the choice of perfusion tracer since 1994, with 37% thallium-201, 
11% Tc-99m sestamibi and 52% Tc-99m tetrofosmin used in 1997. When comparing 
thallium-201 with Tc-99m-labelled agents, the advantages offered by its higher 
myocardial extraction fraction may be at least partially offset by its inferior physical 
properties. But, in a comparison of two Tc-99m —labelled agents, differences such as 
those demonstrated in this study would play a defining role in making a choice of one 
over the other. This is first study to demonstrate a difference in the ability of Tc-99m 
sestamibi and Tc-99m tetrofosmin to estimate ischaemic burden, and is therefore 
expected to have a significant impact on clinical practice.
While there is a considerable amount of data supporting the prognostic value of 
normal and abnormal Tc-99m sestamibi SPECT scans in conjunction with both 
dynamic exercise and pharmaceutical stress testing, such data with Tc-99m
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tetrofosmin is lacking. In the light of the current study, it must be concluded that 
prognostic data derived from studies using Tc-99m sestamibi should not be 
empirically extrapolated to Tc-99m tetrofosmin without large outcome studies.
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9.7 A R E A S  F O R  F U R T H E R  R E S E A R C H
Assessment of diagnostic sensitivity: Although there was a trend in favour of Tc- 
99m sestamibi, the diagnostic sensitivity of the two agents for the detection of 
coronary artery disease was not significantly different in this study. Larger studies are 
required to determine if this trend in favour of Tc-99m sestamibi translates into a truly 
significant difference in the diagnostic sensitivity of the two agents.
Relationship to stress modality: Data from previous animal and small clinical trials 
suggest that there will be no difference in the performance of the two agents if 
exercise or inotropic stress is used, since these modalities induce smaller increases in 
myocardial blood flow compared to vasodilatation. This hypothesis needs to be tested 
in large clinical trials.
Use of gated SPECT imaging: Gated SPECT acquisition was not performed in this 
study. Since the study population consisted of patients with mild to moderate disease 
with no previous myocardial infarction, it is unlikely that gating would have had a 
significant impact on diagnostic sensitivity. However, normalcy rates may have been 
improved, even in the small number of patients with low probability of coronary 
artery disease included in this study. Since gated SPECT imaging is becoming 
increasingly used, and is likely to become standard practice a comparative study using 
this technology will become necessary.
Assessment of prognostic value: The major implication of underestimating 
myocardial ischaemia is that this would undermine the ability of a tracer to risk-
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stratify patients with known or suspected coronary artery disease. Large outcome 
studies are needed to determine if the results of the current study truly reflect a 
difference in the prognostic power of Tc-99m sestamibi and Tc-99m tetrofosmin 
when used in conjunction with vasodilator stress.
Should thallium-201 be the preferred agent for use with vasodilator stress?
Based on the results of this and other studies one could speculate that thallium-201, 
with its high myocardial extraction fraction, is the agent of choice for use with 
vasodilator stress. However thallium-201 has several disadvantages including its 
unsuitability for gated SPECT imaging. Comparative studies are required to 
determine if the advantage of a high myocardial extraction fraction overrides these 
disadvantages.
Diagnostic sensitivity of myocardial perfusion imaging for mild coronary 
disease: One of the concerns raised by the results of this study is the low sensitivity 
of both agents for the detection of disease in this specific population of patients with 
mild to moderate disease. Although previous studies have demonstrated that most 
non-invasive imaging techniques have a relatively lower sensitivity for the detection 
of mild compared to severe disease, 110 study has assessed the diagnostic accuracy of 
myocardial perfusion imaging exclusively in this group of patients.
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A P P E N D I X
Appendix I
PA T IENT I N F O R M A T I O N  S H E E T
Please read the following information. It explains the nature and 
purpose of the study in which you have been requested to participate.
You have been referred to the Department of Cardiology for 
investigations to assess whether there is any blockage in the arteries 
supplying blood to the muscles of the heart, a condition called coronary 
artery disease. One of the methods of doing this is by performing 
radioisotope scans of the heart. There are numerous radioisotope 
compounds that are used for this purpose, and this study proposes to 
compare two of these namely technetium-99m sestamibi and 
technetium~99m tetrofosmin. Both these agents are licensed for clinical 
use and is widely utilised in hospitals all over the world for investigation 
of coronary artery disease. This study has been approved by the 
Northwick Park Hospital Ethics Committee and ARSAC 
(Administration of Radioactive Substances Advisory Committee), UK.
You will have two sets of scans (one set with technetium-99m sestamibi 
and the other with technetium-9 9m tetrofosmin) within 2 to 4 weeks of 
each other. Each set will comprise of one scan done at rest and one scan 
done after intravenous administration of one of two drugs, either 
dipyridamole or adenosine. Both these drugs increase blood flow to the 
heart and are routinely used to increase the diagnostic ability of the 
scans. Some patients may experience transient minor symptoms like 
headache, dizziness or chest pain. The doses of the radioisotopes used 
in this study have been approved by ARSAC and no major side effects 
are known.
If you wish to withdraw from the study, you may do so at any time 
without any obligations. This will not affect you future medical 
treatment. Similarly, if you do not wish to take part in this study, this 
will in no way influence your future management.
The sponsors of the study are adequately insured for this study and 
should any problems arise during the course of the study they will be 
dealt with in accordance with the guidelines described by the 
Association of British Pharmaceutical Industry. A  copy of these 
guidelines is available on request.
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Appendix II
PATIENT CONSENT FORM
Agreement to Participate in a Clinical Study
I, the undersigned, voluntarily agree to participate in the following clinical study:
"Comparison of the extent and severity of vasodilator stress-induced myocardial 
perfusion abnormality with Tc-99m sestamibi and Tc-99m tetrofosmin SPECT 
imaging".
I have read the patient information sheet on the above clinical study and had the
opportunity to discuss details with..................................................... and to ask
questions.
D r ............................has explained to me what has to be done and why. I understand
what will be expected o f me.
I understand that I am free to withdraw from the study at any tine and that my 
withdrawal will not influence my future medical care.
I also understand that my General practitioner will be informed that I am taking part in 
the study.
I consent to permit, under the supervision o f  my hospital Doctor, the study monitor to 
have limited access to my hospital notes to check clinical information relevant to the 
study.
Signed....................................................................................Date.................
I have fully explained the purpose and nature o f this study to this patient.
Signed...................................................................   Date.
Name: Dr...............................................................................
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Appendix III 
GP LETTER
Date
Dear Dr 
RE:
This patient has consented to participate in the following trial: 
"Comparison of the extent and severity of vasodilator stress- 
induced myocardial perfusion abnormality with Tc-99m sestamibi 
and Tc-99m tetrofosmin SPECT imaging".
A  randomised, double-blind and cross-over protocol design will be 
used. After informed consent is obtained, each patient will be randomly 
allocated to either the dipyridamole (Group 1) or adenosine (Group II) 
group, so as to make up a total of 60 patients in each group. In both 
groups they will be randomised to receive either Tc-99m sestamibi or 
Tc-99m tetrofosmin initially and then crossed over to the other agent to 
eliminate selection bias. Of the 60 patients, 10-15 with a low 
probability (<5%) of coronary artery disease. This sup-group may be 
used to calculate normalcy rates to and from a database for 
quantification.
The trial has been approved by the Northwick Park Hospital Ethical 
Committee.
If you have any further queries, please contact me on the following 
number: 0181 864 3232 bleep 163.
Yours sincerely
D R  P S O M A N  
RESEARCH REGISTRAR
175
Appendix IV : SPECT reporting form
View Segment Stress Rest
Distal short axis (1) Anterior
f e y )
(2) Inferior
(3) Lateral
Mid short axis (4) Anterior
(5) Anteroseptal
(6) Inferoseptal
(7) Inferior
(8) Inferolateral
(9) High Lateral
Basal short axis 
f i 7 \15\
\12 J
(10) Anterior
(11) Anteroseptal
(12) Inferoseptal
(13) Inferior
(14) Inferolateral
(15) High Lateral
1. Segmental scoring
0 = normal
1 = slightly reduced
2 = moderately 
reduced
3 = severely reduced
4 = absent
2. Quality
| | poor \Y\ fair
|~~| good excellent
3. Patient diagnosis 
j | normal
□  ischaemia
□  scar
j J  ischaemia and scar
4. Diagnostic certainty 
[ ~ ] definitely normal 
1 1 probably normal 
| ]] equivocal 
[ ~| probably abnormal 
□  definitely abnormal
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u n i v e r s i t y  o f  su r r e y  libr ar y
